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ABSTRACT 
 
 
 The nuclear receptor (NR) superfamily represents a structurally-conserved group 
of ligand-regulated transcription factors. These proteins have critical roles in various 
physiological and pathological processes, including cancer, and have been targets of drug 
therapy. The orphan NR subfamily 4A (NR4A), which includes the NR4A1 (Nur77), 
NR4A2 (Nurr1), and NR4A3 (Nor-1) genes has been implicated in adult solid tumors and 
have been characterized as pro-tumorigenic mediator of cell proliferation, transformation, 
migration, and drug resistance. Alternatively, in leukemia, NR4A1 and NR4A3 have been 
described as tumor suppressors in hematologic malignancies. Members of the NR4A 
family are commonly overexpressed in cancer and this has been attributed to their 
regulation by other oncogenic signaling pathways. 
 
 Despite the understanding of signaling cascades that lead to overexpression of the 
NR4A members, little is known about their regulation by microRNAs (miRNAs). 
miRNAs are small, non-coding, endogenous RNAs that are transcribed, processed, and 
used to direct cellular proteins that destabilize or block translation of target mRNA. In 
this study, we first sought to determine the miRNAs that are responsible for regulating 
NR4A2. Using a 3ʹ UTR reporter assay, we identified miR-34 as a regulator of the NR4A2 
through its 3ʹ UTR, which was confirmed using mutagenesis of the predicted binding 
region of the miR-34 seed region to its target site. We demonstrated that overexpression 
of exogenous or induction of endogenous miR-34 expression downstream of p53 
activation by Nutlin-3a was associated with decreased endogenous NR4A2. Additionally, 
overexpression of NR4A2 was capable of suppressing the activation of p53 target genes, 
and was also able to attenuate the sensitivity of cells to the anti-proliferative effect of 
Nutlin-3a. 
 
 We further explored the roles of the NR4A family in pediatric cancer, an area that 
has not been fully investigated. We first determined that the members of the NR4A 
family are overexpressed in rhabdomyosarcoma (RMS) cell lines compared to normal 
muscle cells. Knockdown of NR4A1 or NR4A2 led to a reduction in cell proliferation and 
transformation, while knockdown of NR4A2 could also affect cell migration. Using a 
microarray approach, we sought to investigate the transcriptome-level changes in 
response to NR4A knockdown, and determined that knockdown of NR4A2 led to a 
unique gene signature, while NR4A1 and NR4A3 knockdown had large overlaps in 
expression changes. These unique gene expression changes in response to NR4A2 
knockdown could explain the unique effects that NR4A2 has on migration. 
 
 Overall, this study has discovered miR-34 as a novel regulator of NR4A2, and 
places NR4A2 in a potential feedback mechanism involving p53, miR-34, and NR4A2. 
This could indicate that NR4A2 mediates at least some of its pro-oncogenic effects 
through the inhibition of p53, which is relieved by p53 itself upon activation. 
Alternatively, NR4A2, is shown to have other roles in cancer, potentially through novel 
downstream target genes. These data may be used in understanding the effects of miR-34 
 vi 
replacement therapy, as this method of treatment is progressing through clinical trials, 
allowing us to understand the diverse regulator cascades being modulated.  
 vii 
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CHAPTER 1.    INTRODUCTION 
 
 
Nuclear Receptors 
 
 
Discovery of the nuclear receptor superfamily 
 
 Three decades ago, the glucocorticoid (GR) and estrogen (ER) receptors were the 
first described nuclear receptors (NRs) [1-4], and since then much has been discovered in 
regard to this group of key transcriptional regulators in physiological and pathological 
events. Following characterization of GR and ER, additional proteins which shared 
conserved domains began to be discovered [5], and now the human NR superfamily 
consists of 48 genes that encode a highly homologous set of transcription factors. This 
superfamily of proteins shares similar structural organization, composed of modular 
domains [6, 7] that include (listed from N- to C-terminal) an N-terminal domain which 
harbors an activation function-1 (AF-1) region, a DNA-binding domain (DBD), a flexible 
hinge region, and a C-terminal ligand-binding domain (LBD) that contains an AF-2 
region. 
 
 These mostly ligand-regulated transcription factors control target gene expression 
through mechanisms typically involving ligand binding, dimerization, nuclear 
localization, and recruitment and association with coregulators at sites in gene promoters 
(Figure 1-1). Upon initial cloning of the various NR members, those lacking a defined 
ligand were termed ‘orphan’ receptors—some of which have remained ‘orphans,’ while 
others have been ‘adopted’ following identification of their cognate ligand. Those with 
known ligands typically are activated by steroid or thyroid hormones, vitamins, fatty 
acids, bile acids, sterols, or xenobiotics [8]. Several key members of the NR family have 
been utilized as drug targets [9, 10], and it was reported that 13% of FDA-approved drugs 
were NR modulators, representing the second-leading class of drug targets at that time 
[11]. Additionally, other NRs, such as PXR and CAR, have been studied for their roles in 
regulating transcriptional target genes that are involved in drug metabolism, having 
implications in drug–drug interactions and drug toxicity [12, 13]. 
 
 
Domain structure and function 
 
N-terminal domain and AF-1 
 
 The N-terminal domain of NRs is divergent among the different NR subfamilies 
and isoforms, with large variability in the size of this domain. Encoded in the N-terminal 
domain is the AF-1 region, which can function independently of ligand binding [14]. This 
region is also important in post-translational regulation of NR function through 
phosphorylation or protein-protein interactions [15-18]. These regulatory mechanisms 
can serve to affect the protein levels or transcriptional activity of the NR. 
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Figure 1-1. The nuclear receptor signaling pathway. 
The nuclear receptor (NR) signaling cascade begins with an endogenous or synthetic 
ligand for a specific NR enters the cell and binds to the ligand-binding domain (LBD) of 
the NR. This triggers a dimerization of either homo- or hetero- NR binding partners. This 
binding causes an exposure of a nuclear localization signal, at which time the dimer is 
translocated to the nucleus where it recruits coactivators and the transcriptional 
machinery. This complex directs the transcription of NR target genes through its DNA-
binding domain (DBD) depending on specific recognition elements in the DNA. The 
resultant gene is transcribed into protein and subsequently mediates the biological 
response of NR activation. 
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DNA-binding domain 
 
 The DBD is the most conserved region among the members of the NR 
superfamily. This region contains two zinc finger motifs, which direct the DNA-binding 
activities of each NR to double stranded DNA at receptor-specific response elements 
[19]. These DNA response elements have specific sequences to confer the NR-specific 
binding activities for the regulation of corresponding target genes. The DBD also 
contains a nuclear localization signal (NLS) which, when exposed, directs NR complexes 
to the nucleus upon ligand binding [20]. 
 
Ligand-binding domain and AF-2 
 
 The LBD is the second most conserved region among NRs, and is the domain that 
makes NRs unique from other transcription factors. The LBD is responsible for binding 
endogenous or synthetic ligands to activate downstream NR signaling. This domain also 
contains the AF-2 region, which directs ligand-dependent recruitment of coregulators 
[14]. The LBD encodes the major interface for NR dimerization upon ligand binding 
[21]. Using sequence-based and crystallographic studies, it was determined that NRs 
share common folding in the LBD region [22], which consists of a series of α-helices, 
referred to as H1?H12. These helices form the pocket in which the ligand binds. Binding 
of ligand causes a shift of the helices with H12 closing the cavity for a more stable holo-
conformation [23]. H12 encodes part of the AF-2 which, when closed in the holo-form, 
presents a hydrophobic cleft for the coactivator recruitment. 
 
 
Nuclear receptors and cancer 
 
 In addition to NRs having important roles in normal physiological contexts, NR 
dysregulation can occur and lead to various disease states including cancer. Examples of 
this include several hormone-dependent cancers, such as breast and prostate cancer, 
where NRs play a critical role in the development, progression, and resistance of these 
malignancies to therapy. As a result, these NRs have been targeted by small molecule 
modulators and hormone therapy as a way to treat disease. 
 
Glucocorticoid receptor 
 
 The glucocorticoid receptor (GR) serves as the receptor for natural (cortisol) and 
synthetic (dexamethasone, prednisone/prednisolone, and budesonide) glucocorticoids 
(GCs). As the physiological function of GCs are to minimize inflammation, these steroid 
molecules were first used therapeutically for the treatment of rheumatoid arthritis [24]. 
Synthetic GCs are commonly prescribed for various diseases with inflammatory 
conditions, including asthma and dermatitis [25]. GCs have also been used in the 
treatment of lymphoid malignancies, including acute lymphoblastic leukemia (ALL) [26]. 
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 The therapeutic response to GCs in ALL can be attributed primarily to the 
transcriptional activity of GR and is dependent on GC binding to GR [27]. Binding of GC 
to GR leads to cytoplasmic-to-nuclear translocation of GR, where it can then bind to 
target gene promoters and cause transactivation or repression of gene expression. Some 
of the GC-mediated effects include inhibition of cell proliferation and induction of 
apoptosis. Genes induced by GCs include Bim, Bid, and Bad, which promote apoptosis, 
while genes involved in inhibition of apoptosis (Bcl-2, Mcl-1, and Bcl-xL) are suppressed 
by GCs [27], leading to a GC-mediated apoptosis during therapy. Resistance to GCs can 
occur through various methods, including low GR expression in cells [28], mutations in 
GR [29, 30], or other alterations that affect GR directly such as overexpression of CASP1 
[31]. 
 
Estrogen receptor 
 
 The estrogen receptor alpha (ERα) and beta (ERβ) are receptors for endogenous 
estrogens, which includes estrone (E1), 17β-estradiol (E2), and estriol (E3). Estrogen is 
important in normal physiology, and is normally secreted by the ovaries in 
premenopausal women. High levels of estrogen have been associated with cancer in 
various tissues of both women and men, although the understanding of estrogens in 
cancer progression is understood predominantly from studies in breast and endometrial 
cancers [32]. The ability for estrogen to promote cancer development and progression is 
mediated mostly through ERα-mediated transcriptional activation of target genes which 
include c-Myc [33] and cyclin D1 [34] to promote cell proliferation, and Bcl-2 [35] to 
block the apoptotic response and promote cell survival. As a normal physiological 
response of promoting new blood vessel formation (angiogenesis) in the uterus, estrogen 
can also induce genes responsible for this process in breast cancer cells [36], which is a 
critical component of tumor progression, allowing new blood flow to developing tumor. 
Although ER expression appears important for primary tumor formation, the loss of ER 
expression portends a more aggressive, invasive, and deadly disease [37] with a high 
propensity to metastasize, at which time targeting ER is no longer feasible. 
 
 Targeting of ERα with small molecule modulators has been a focus, and 
somewhat effective, strategy of treating hormone-dependent cancers. Tamoxifen, 
developed as the first selective estrogen receptor modulator (SERM), is able to reduce 
breast cancer recurrence and mortality, and is used as the front line drug for ER-positive 
breast cancers. SERMs are small molecules that are able to mimic estrogen and bind to 
the ER LBD, but rather act as an antagonist of ER function by blocking endogenous 
estrogen signaling through this axis [38]. Development of resistance is a major problem 
of tamoxifen and other therapies for breast cancer patients. Cytochrome P450 enzyme 
CYP2D6 is the primary metabolizer of tamoxifen into its active metabolite and, as a 
means of resistance, CYP2D6 polymorphisms leads to lower clinical efficacy [39]. 
 
  
 5 
Androgen receptor 
 
 The androgen receptor (AR) serves as the ligand for endogenous testosterone and 
its more active metabolite form, 5α-dihydrotestosterone. These androgens are formed in 
the testes by Leydig cells, and serve to regulate gene expression that primarily directs 
male sexual development. Androgens and AR also stimulate proliferative and survival 
pathways in prostate cells, and the dysregulation of these actions leads to development of 
prostate cancer [40]. A common test to indicate the need for patient surveillance or 
biopsy is measurement of serum levels of prostate-specific antigen (PSA), a well-
characterized target gene of AR [41], which indicates increased androgen signaling. 
Studies have shown that 159 different mutations in AR itself can predispose men to 
develop prostate cancer [42]. 
 
 Classically, removal of the testes was found to cause prostate cancer regression 
through the deprivation of androgen stimulation. Synthetic, non-steroidal antiandrogens 
have been developed that are capable of blocking androgen signaling, and these include 
flutamide, bicalutamide, and nilutamide [40]. Although structural studies have not 
confirmed their mechanism of action, it is believed that these antiandrogens bind to the 
LBD of AR, competing out the endogenous androgen binding. Resistance to androgen 
deprivation and blockade can develop, at which point the disease becomes deadly and 
difficult to treat, and is referred to as castration-resistant prostate cancer (CRPC) [43]. 
Several mechanisms of CRPC have been described, including increased AR expression 
and mutations in AR which cause it to either become activated by other endogenous 
steroids as a means to bypass the need for androgens or insensitive to the actions of 
antiandrogens. 
 
Orphan nuclear receptors 
 
 Those NRs which have no identified endogenous ligands are classified as orphan 
NRs. This subset of receptors affect a multitude of physiological responses. Due to the 
absence of identified ligands, studies suggest that these NRs can act independently of 
ligand through constitutive activation, influenced through post-translational modifications 
or protein-protein interactions. Much like their ligand-associated family members, the 
orphan NRs can positively or negatively regulate gene expression through their DBD 
region. 
 
 Additionally, the actions of orphan NRs have been linked to cancer development 
and progression [44], which includes the known functions of one orphan NR subfamily, 
the NR4A receptors. The NR4A family, which includes NR4A1 (Nur77), NR4A2 
(Nurr1), and NR4A3 (Nor-1), has been demonstrated to primarily have oncogenic roles in 
many adult solid tumors as a result of oncogene and tumor suppressor signaling in cancer 
[45]. NR4A1 and NR4A3 have also been shown to be downregulated and act as tumor 
suppressors in leukemia, with deletion of these NRs leading to rapid acute myeloid 
leukemia (AML) in mice [46]. Research primarily led by Safe and colleagues has 
targeted the NR4A receptors, primarily NR4A1, through the development of small 
molecule methyl-substituted diindolylmethanes (C-DIM) as inhibitors of 
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NR4Amoncogenic activity [47-49]. Alternatively, some C-DIMs and another compound, 
cytosporone B, can activate proapoptotic functions of NR4A1 [49-55]. Another route of 
NR4A targeting has included altering the subcellular localization of NR4A1 to promote 
mitochondrial-associated apoptosis [56] or through the targeting of NR4A1 interactions 
with other proteins [57-59]. 
 
 
microRNAs 
 
 
microRNA biogenesis and function 
 
 microRNAs (miRNAs) are small, endogenous, non-coding RNAs of 
approximately 22 nucleotides in length. Genes encoding miRNAs are transcribed from 
DNA by RNA polymerase II (Pol II) [60]. miRNA genes can be encoded in introns or 
exons of non-coding or protein-coding regions, and can exist alone or as a polycistronic 
transcript of multiple miRNAs. Transcription by Pol II forms a primary miRNA (pri-
miRNA), which is then processed by the RNase Drosha to form a precursor miRNA (pre-
miRNA) [61]. The pre-miRNA is exported from the nucleus by Exportin 5 into the 
cytoplasm [62]. Further processing occurs in the cytoplasm by the RNase Dicer, cleaving 
it into a small RNA duplex [63]. This short RNA duplex is loaded into a pre?RNAi-
induced silencing complex (RISC), which contains an Argonaute (AGO) protein [64]. 
The pre-RISC is responsible for unwinding the miRNA duplex, retaining only the active 
strand.  
 
Upon formation of the mature miRNA-containing RISC, this active complex is then 
directed primarily to 3′ untranslated regions (UTR) in target mRNAs, acting as a guide to 
direct gene or protein suppression [65]. The miRNA recognizes its targets based on 
nucleotide complementarity within the 3ʹ UTR, and partial pairing of the mature miRNA 
with the 3ʹ UTR can be sufficient for target recognition [66]. The critical nucleotides for 
miRNA-mediated suppression are in positions 2–7 at the 5ʹ end of the miRNA, which is 
referred to as the seed region of the miRNA [67]. The RISC then directs mRNA 
degradation, destabilization, or translational repression of target mRNAs [65], resulting 
in miRNA-mediated suppression of protein expression (Figure 1-2) and ultimately 
reduced protein function and biological activity. 
 
 
miRNAs and cancer 
 
 Dysregulation of miRNAs has been attributed to the development and progression 
of cancer [68]. This is accomplished depending on the particular genes that a miRNA is 
responsible for targeting, with an alteration in the expression of the miRNA causing a 
resultant change in its target genes. Much like protein-coding genes that are involved in 
cancer, miRNAs can be classified as either oncomiRs or tumor-suppressor?like miRNAs 
(Figure 1-3). 
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Figure 1-2. The microRNA biogenesis pathway.  
MicroRNAs (miRNAs) are first transcribed from genes encoding each respective miRNA 
by RNA polymerase II (Pol II). The resulting transcript is referred to as pri-miRNA, and 
can exist as a single miRNA (monocistronic) or as a miRNA cluster (polycistronic). The 
pri-miRNA is then processed by the RNAase Drosha to form the pre-miRNA form. The 
pre-miRNA is then exported from the nucleus into the cytosol by Exportin-5, where it 
becomes further processed by the RNase Dicer. The duplex miRNA now incorporates 
into an Argonaute (Ago2)-containing RNAi-induced silencing complex, where the duplex 
unwinds and the unstable star-strand (miR*) becomes degraded. Using the loaded active 
miRNA strand as a guide, the RISC binds to the 3ʹ UTR of miRNA target genes, leading 
to mRNA transcript degradation or inhibition of ribosomal translation of mRNA into 
protein. 
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Figure 1-3. Dysregulation of miRNAs can contribute to cancer.  
MiRNAs are able to act as tumor suppressors or oncogenes (referred to as oncomiRs) 
depending on the target genes that they suppress. Tumor-suppressor like miRNAs are 
described as targeting a gene that normally acts as an oncogene, but when this miRNA 
has reduced or absent expression, the oncogene is no longer suppressed and can increase 
in expression to promote cancer phenotypes. An oncomiR is a miRNA that targets a 
tumor suppressor, and the aberrant overexpression of this miRNA leads to decreased 
tumor suppressor expression and function, resulting in unchecked tumorigenesis. Cancer-
related miRNAs have been shown to contribute to multiple steps of cancer development, 
progression and metastasis, and therapeutic resistance. 
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Tumor-suppressor–like miRNAs 
 
 Tumor-suppressor-like miRNAs are those miRNAs that typically are responsible 
for regulating genes that promote cell proliferation, survival, or other tumor-promoting 
processes. As are tumor suppressor proteins, the expression of tumor-suppressor?like 
miRNAs are decreased or lost due to factors such as loss in transcription factor 
regulation, epigenetic silencing, or genomic deletion [69]. This loss in miRNA expression 
allows the resulting target gene to become increased in expression, contributing to factors 
that promote cancer at multiple steps of oncogenesis. 
 
 One example of a tumor-suppressor?like miRNA is the miR-34 family. This 
family of miRNAs consists of three isoforms (miR-34a/b/c) that share a common seed 
region. The miR-34a family is transcriptionally regulated by the tumor suppressor protein 
p53 [70, 71], and has been attributed to partially carrying out tumor suppressive functions 
of the p53 response. As such, loss of p53 activity through deletion or mutation could be 
attributed to a decrease in miR-34 expression. Additionally, miR-34 expression can be 
lost through epigenetic silencing [72] or through deletions, as in the case of 
neuroblastoma [73, 74]. Genes that are regulated by miR-34 include those involved in 
cell cycle progression, antiapoptotic and survival responses, and migration and metastasis 
[75]. 
 
OncomiRs 
 
 Alternatively, miRNAs can act similar to oncogenes. These miRNAs are termed 
oncomiRs, and are responsible for regulating genes that normally have tumor suppressive 
function. OncomiRs become increased in expression, typically by increased transcription 
factor signaling at the transcriptional level [68]. One example of an oncomiR includes 
miR-21, which was the first described oncomiR [76]. miR-21 regulates genes such as 
PTEN [77] and other tumor suppressor genes to elicit it’s cancer-promoting effects, and it 
is found to be overexpressed in many tumor types. 
 
 
Hypothesis and Specific Aims 
 
 Research by other groups suggests that overexpression of NR4A1 and NR4A2 
could promote cell proliferation, migration, transformation, and survival in cancer. 
Understanding how members of the NR4A subfamily are regulated and determining their 
roles in cancer is the first step in understanding their biological relevance and usefulness 
as therapeutic targets. Although much is known about the cell signaling events that 
regulate NR4A expression, very little is known regarding the contributions of miRNAs in 
regulating this NR subfamily. Additionally, the function of NR4A NRs in pediatric 
malignancies has not been investigated. 
 
 We hypothesize that due to the previously described overexpression of NR4A 
family members in solid tumors, particularly NR4A1 and NR4A2, that regulation of the 
NR4A members by tumor-suppressor–like miRNAs is a contributing factor to their 
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overexpression, and that in turn, NR4A family members contribute to cancer phenotypes 
through their control of gene expression. To test this hypothesis, we carried out the 
following specific aims: 
 
1. Investigate the regulation of NR4A2 by miRNAs and characterize the relevance 
of this regulatory mechanism in cancer. 
2. Determine the roles of the NR4A receptors in caner and examine the gene 
expression changes as a result of NR4A modulation. 
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CHAPTER 2.    THE INTERPLAY OF NR4A RECEPTORS AND THE 
ONCOGENE–TUMOR SUPPRESSOR NETWORKS IN CANCER* 
 
 
Introduction 
 
 The human nuclear receptor (NR) family is a group of structurally related 
transcription factors that regulate specific gene expression in a ligand-dependent manner. 
This superfamily of receptors constitutes an important group of drug targets that are 
useful in identifying compounds that affect a wide range of physiological and 
pathological events [9]. NRs share a common structural arrangement that consists of an 
N-terminal domain containing an activation function–1 (AF-1) region, a DNA-binding 
domain, a hinge region, and a C-terminal ligand-binding domain (LBD) that can also 
encode an AF-2 domain. NR subfamily 4 group A (NR4A) is composed of three 
members: Nur77 (NR4A1, also known as nerve growth factor IB or NGFIB), Nurr1 
(NR4A2), and Nor-1 (NR4A3). 
 
 Members of the NR4A subgroup respond to various stimuli, and their expression 
can be induced by mitogens, stress, and apoptotic signals, implicating their roles in 
multiple biological processes [78, 79]. The NR4A receptors are classified as orphan 
receptors, having no known physiological ligands, and do not contain a typical ligand-
binding domain structure common to other NRs [78, 80-82] although recent evidence 
suggests that unsaturated fatty acid metabolites could serve as the missing ligand for 
Nur77 [83]. Typical NRs have a ligand-binding domain containing a hydrophobic cleft 
for ligand- and coactivator-binding, but structural studies show that the NR4A subgroup 
contains an atypical ligand-binding groove that is hindered by bulky side groups of 
hydrophobic residues. Thus, the NR4A receptors are believed to be regulated in a ligand-
independent manner, and a growing amount of literature supports the notion that these 
receptors are regulated largely by post-translational modifications and protein-protein 
interactions and that their expression and localization within the cell influences their 
cellular functions. 
 
 
NR4A Receptors in Cancer 
 
 The NR4A receptors promote or suppress tumors depending on specific cellular 
context. For example, Nur77 is overexpressed in cancer cell and tissue samples of 
multiple origins, causing increased proliferation and survival in these cells and tissues 
[84] at least partly via upregulation of several target genes, including cyclin D2 [16], 
E2F1 [85], survivin [47], and thioredoxin domain–containing 5 (TXNDC5) [48], which  
 
 
-------------------- 
* Reprinted with permission from Elsevier. Beard, J.A., A. Tenga, and T. Chen, The 
interplay of NR4A receptors and the oncogene-tumor suppressor networks in cancer. Cell 
Signal, 2015. 27(2): p. 257-66.  doi: http://dx.doi.org/10.1016/j.cellsig.2014.11.009
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are mediators of cell cycle progression, apoptotic inhibition and reactive oxygen species 
(ROS) regulation (Figure 2-1). In addition, loss-of-function  studies of Nur77 have 
demonstrated its importance in cell proliferation and survival [86], with the consensus 
being that Nur77 knockdown reduces cellular growth rate and angiogenesis and induces 
intrinsic and extrinsic apoptotic pathways. It is important to note that many loss-of-
function studies are performed on non-stimulated cells to determine the role of basal, 
endogenous Nur77. Conversely, in cells stimulated with various apoptosis-inducing 
agents, Nur77 plays a role in cell death through both transcription-dependent and -
independent mechanisms (Figure 2-1). Because of the dual and opposite roles of Nur77 
in cell proliferation and death, many studies have been focused on therapeutically 
targeting Nur77 to impede its oncogenic functions while coaxing it to activate the cellular 
death program [87]. These efforts would rely on the fact that non-tumor tissue will 
express Nur77 at much lower levels, making these tissues less responsive to Nur77-
mediated apoptosis-inducing agents. 
 
 Nurr1 has been implicated in cancer progression although its cancer-related target 
genes have not been characterized. Nurr1 knockdown decreases anchorage-independent 
growth, suggesting that Nurr1 plays a role in cell transformation [88, 89]. The protein 
promotes migration but not overall proliferation in bladder cancer [90], although it does 
affect cell proliferation in lung and breast cancer [91, 92]. Nurr1 expression is higher in 
squamous cell carcinoma (SCC) samples than in normal tissues of patients with SCC, and 
induction of Nurr1 expression in SCC leads to increased resistance to 5-fluorouracil [93], 
suggesting a role for Nurr1 in drug resistance [93, 94]. Additionally, Nurr1 
overexpression contributes to protection from doxorubicin-induced apoptosis by 
diminishing the p53 response [95]. 
 
 In patients with breast cancer, Nurr1 expression in normal breast epithelium is 
higher than that in tumor tissue and has been positively correlated with favorable 
prognosis [92]. Conversely, the same study found that knockdown of Nurr1 in breast 
cancer cell lines diminished xenograft tumor growth. The different roles of Nurr1 in 
different tissues point to possible context-dependent effects of Nurr1, which might also 
depend on the intracellular localization of Nurr1 protein as cytoplasmic expression of 
Nurr1 in bladder cancer was correlated with decreased patient survival [90]. However, 
other studies using either stimulated endogenous or overexpressed exogenous Nurr1 have 
not clearly determined its subcellular localization. 
 
 Less is known about Nor-1’s functions in cancer, although some key findings 
have been made. For example, Nr4a1−/−;Nr4a3−/− double-knockout mice develop acute 
myeloid leukemia (AML) with very rapid onset, dying within 2 to 4 weeks [46]. The 
myeloid cells from these mice have more S- and G2/M-phase populations and fewer 
annexin V–positive cells than do those of wild-type mice. The decrease in apoptotic cells 
was attributed to a reduction in extrinsic cell death signaling, as indicated by a decrease 
in Fas ligand and TRAIL expression. Expression of Nur77 and Nor-1 were dramatically 
reduced in AML patient samples. Together, these data suggest that these two NR4A 
receptors can play overlapping tumor suppressive roles in leukemia, as NR4A single-
knockout mice do not develop cancer [96, 97]. The functional redundancy of Nur77 and  
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Figure 2-1. Nur77 mediates cell death or survival through localization-dependent 
and –independent mechanisms.  
As a nuclear transcription factor, Nur77 largely promotes cell proliferation and survival 
through regulation of specific target genes (i.e., cyclin D2, E2F1, survivin, TXNDC5). 
Additionally, some agonists of Nur77 transactivation are able to mediate transcription-
dependent cell death. A major mechanism of Nur77-mediated cell death is the nuclear 
export of Nur77-RXRα heterodimers, which is suppressed by the CHD1L oncogene. 
Cytoplasmic Nur77 can activate mitochondrial- or ER-associated cell death by interacting 
with membrane-bound Bcl-2. 
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Nor-1 was further confirmed in a follow-up study investigating genome-wide 
transcriptional changes in response to NR4A restoration in AML [98]. Nur77 and Nor-1 
shared overlapping gene signatures by regulating 97% of the same transcripts, and re-
expression of either NR4A receptor was able to elicit tumor-suppressive functions by 
reducing proliferation and increasing apoptosis. Furthermore, NR4A re-expression 
suppressed MYC and its accompanying oncogenic signature in multiple AML cells. 
 
 Another perturbation of Nor-1 function occurs in extraskeletal myxoid 
chondrosarcoma (EMC). Researchers identified a recurrent translocation of Nor-1 (also 
called TEC, Translocated in Extraskeletal Chondrosarcoma) with the EWS gene that 
encodes a novel EWS-TEC fusion protein in EMC tumors [99]. This oncogenic fusion 
protein binds to and regulates the NGFI-B Response Element (NBRE), with 250-fold 
greater transactivation capacity than that of wild-type Nor-1 [100]. Because EWS-TEC 
fusion protein can bind to the NBRE, several studies have been focused on the 
differential transactivation of target genes of EWS-TEC and Nor-1 [101, 102]. Analysis 
of 16 EMC tumors showed that 15 cases contained EWS-TEC fusion transcripts [103]. 
Introduction of the EWS-TEC oncogenic fusion protein into a chondrogenic cell line did 
not increase the proliferation rate but allowed cells to grow past contact inhibition to form 
small clusters of cells and increased anchorage-independent growth [104]. Nor-1 also 
forms fusion proteins with other proteins in EMC [105, 106]. 
 
 
NR4A Receptors and MAPK 
 
 
MAPK and cancer 
 
 The mitogen-activated protein kinase (MAPK) pathway is induced by a wide 
range of signals, including growth factors, cytokines, and stress, and is responsible for 
almost every cell function, including proliferation, differentiation, cell death, and 
migration. The six different MAPK pathways include extracellular signal-regulated 
kinase (ERK) 1/2, ERK 3/4, ERK5, ERK 7/8, Jun N-terminal kinase (JNK) 1/2/3, and 
p38 (ERK6), as reviewed in [107]. Typically, an external signal triggers the signaling 
cascade through a membrane-bound receptor, followed by recruitment of G-proteins such 
as Ras, Rac, and Rho and, subsequently, of downstream kinases such as Raf and MAPK 
kinase kinase (MEKK), which phosphorylate and activate MAPK kinase (MEK). 
Activated MEKs then phosphorylate and activate MAPKs [107], which will 
phosphorylate either transcription factors to modulate target gene expression or other 
kinases to regulate critical cellular events. Because the MAPK pathway is involved in 
almost every cellular process, it is understandable that dysregulation of this pathway 
could cause cancer. 
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Regulation of NR4A receptors by MAPK 
 
 Phosphorylation of Nur77 by MEK-ERK signaling has been described by several 
groups. Epidermal growth factor (EGF), an activating signal for ERK2, causes 
phosphorylation of Nur77 at threonine 142 [108], a phosphorylation site that stabilizes 
Nur77 [109], consistent with the phosphorylation-mediated stability of other nuclear 
receptors. Interestingly, EGF enhances the interaction of Nur77 with prolyl isomerase 
Pin1, and the isomerization of phosphorylated Nur77 requires ERK2- (and JNK1)-
mediated phosphorylation [110]. This phosphorylation-dependent isomerization prevents 
degradation of Nur77, thereby increasing its transactivation activity and promoting its 
pro-mitogenic effect. ERK2 is responsible for phosphorylation of Nur77 at serine 431, a 
phospho-residue important for both the Nur77-Pin1 interaction and increased 
transactivation mediated by Pin1. 
 
 ERK2 activation upon EGF treatment causes Nur77 nuclear localization and 
prevents its cytosolic induction of apoptosis [111], but the opposite phenotype occurs in 
T-cells. Inhibiting MEK1 decreases expression of Nur77 in T-cells [112] and prevents its 
nuclear export and mitochondrial localization [113], demonstrating the role of ERK 
signaling in Nur77-induced cell death. Ribosomal S6 kinase 2 (RSK2), an effector kinase 
of MEK-ERK, phosphorylates Nur77 at serine 354 [113, 114] and positively regulates 
Nur77’s nuclear export and subsequent mediation of apoptosis. Other groups have 
reported phosphorylation of Nur77 by ERK5, but not by ERK2, in T-cells that caused 
increased Nur77 transcription and induction of apoptosis [115, 116]. 
 
 Activation of ERK1/2 signaling is positively associated with the nuclear 
localization of Nur77 and negatively associated with the ability of fenretinide to induce 
apoptosis [117]. Inhibiting MEK-ERK and treating with fenretinide enhance the cytosolic 
localization of Nur77 in fenretinide-resistant HepG2 cells, but activating MEK-ERK 
prevents this event in fenretinide-sensitive HuH-7 cells, demonstrating a role for ERK 
signaling in the drug resistance of liver cancer cells. In another study, constitutive 
signaling through BRAF-MEK-ERK was shown to positively regulate the expression of 
both Nur77 and Nurr1 via inhibition of BRAF and MEK1/2 [118], implicating this 
commonly mutated and hyperactive pathway as one of the causes of increased Nur77 
levels in cancers. In addition, the p38 MAPK pathway can also modulate the activity of 
Nurr1. For example, upon activation by apoptosis signal–regulating kinase 1, p38 
phosphorylates Nurr1, leading to synthesis of melanin, a pigment important in protecting 
skin, hair, and eyes from harmful elements [119]. 
 
 In another study, fibroblast growth factor 8b (FGF-8b) induced the expression of 
all three NR4As in MC3T3-E1 preosteoblastic cells [120]. Furthermore, the effect of 
FGF-8b was mediated through the MAPK, phosphatidylinositol 3-kinase (PI3K), and 
protein kinase C (PKC) pathways. Proliferation of these cells can be increased by FGF-
8b, and overexpression of Nur77 and Nurr1 further enhance this proliferative effect and 
decrease apoptosis. Therefore, the MAPK pathways regulate the levels, sub-cellular 
localizations, and activities of the NR4A receptors. 
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NR4A Receptors, PI3K-AKT, and mTOR in Proliferation and Survival 
 
 
PI3K-AKT and cancer 
 
 The PI3K-AKT signaling axis is a major regulator of cell proliferation and 
survival, acting downstream of growth factors and receptor tyrosine kinases in parallel 
with MAPK signaling [121]. PI3K heterodimers consist of regulatory and catalytic 
subunits, which are responsible for PI3K regulation and downstream signaling, 
respectively. Upon receptor tyrosine kinase activation and recruitment of PI3K to the 
plasma membrane, the primary function of PI3K is to add a phosphate group to 
phosphatidylinositol 4,5-bisphosphate (PIP2), converting it to phosphatidylinositol 3,4,5-
trisphosphate (PIP3) [122] to flip the “on” switch for downstream signaling. PIP3 recruits 
AKT kinase to the plasma membrane, enabling its phosphorylation and activation by 3-
phosphoinositide-dependent protein kinase-1 (PDK1) [123, 124]. Conversely, AKT 
signaling can be turned off through the phosphatase PTEN, which converts PIP3 back to 
PIP2 [125, 126]. AKT can inhibit apoptosis to promote cell survival by phosphorylating 
and inhibiting both pro-apoptotic Bad [127] and caspase-9 [128]; enhance cell-cycle 
progression by phosphorylating and inactivating glycogen synthase kinase 3 beta 
(GSK3B), leading to stabilization of cyclin D1 [129]; and increase cell growth by 
stimulating the mechanistic target of rapamycin (mTOR) pathway to promote protein 
synthesis [130]. 
 
 Alterations in the PI3K-AKT pathway have been identified in various cancer 
types and include mutations that directly increase PI3K and AKT activity [121, 131] and 
inactivate the tumor suppressor PTEN [132-134]. Mice that are heterozygous for PTEN 
develop an array of tumor types [135] due to uncontrolled PI3K-AKT signaling. Aberrant 
AKT signaling can also lead to inactivation of tumor suppressor p53 [136], with the 
hyperactivation of PI3K-AKT in cancer ultimately leading to increased cell survival and 
proliferation and contributing to tumor growth, metastasis, and angiogenesis through 
modulation of downstream effectors, including NR4A receptors. 
 
 
The interplay of NR4A receptors and PI3K-AKT 
 
 AKT phosphorylates Nur77 [137-139] to negatively regulate its function in 
mediating cell death. Specifically, AKT phosphorylates human Nur77 at Ser-351 (Ser-
350 in rats) in the DNA-binding domain [139], a phosphorylation site that inhibits Nur77 
transcriptional activity [140]. AKT-mediated phosphorylation of Nur77 occurs in the 
cytoplasm in a PI3K-dependent manner. More importantly, phosphorylation of Nur77 by 
AKT decreases the transcriptional activity of Nur77 by 50%-85%. Additionally, the other 
two NR4A members, Nurr1 and Nor-1, also have a similar phosphorylation motif, so it is 
likely that AKT also phosphorylates Nurr1 and Nor-1, although this has not been 
investigated. Furthermore, AKT directly inhibits Nur77’s DNA binding activity [138]. 
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 In addition to inhibiting its DNA binding and transcriptional activity, AKT also 
prevents Nur77 from inducing apoptosis in T-cell hybridomas [138]. To inhibit apoptosis 
and increase cell survival, AKT phosphorylation of Nur77 can be considered to be a 
“priming” step for an interaction with 14-3-3 protein, which recognizes the 
phosphorylated motif near the Ser-351 residue. This protein-protein interaction, which 
only occurs with wild-type Nur77 following AKT phosphorylation, is similar to AKT-
mediated phosphorylation of Bad and its subsequent interaction with 14-3-3: both 
protein-protein interactions prevent the protein (Nur77 or Bad) from interacting with Bcl-
2 and causing subsequent apoptosis [127]. By using a DNA-binding domain deletion 
mutant of Nur77 that readily localizes to the mitochondria and induces apoptosis [141], 
researchers showed that overexpressing AKT blocks mitochondrial association with Bcl-
2 and causes a diffuse cytoplasmic localization of Nur77 [137]. Because the Nur77 DNA-
binding domain deletion mutant lacks the Ser-351 residue, this experiment also showed 
that AKT can phosphorylate cytoplasmic Nur77 at the N-terminus. 
 
 AKT can also act on nuclear Nur77, preventing its nuclear export and subsequent 
apoptosis [137, 142]. Overexpression of constitutively active AKT can overcome the 
effects of MEKK1-induced nuclear export of Nur77, retaining it within the nucleus [142]. 
The effect of AKT depends on Ser-351 of Nur77: if Ser-351 is replaced with alanine, the 
Nur77 mutant migrates to and remains in the cytoplasm in response to MEKK1 
activation, regardless of AKT status. Inhibition of PI3K-AKT or knockdown of AKT 
restores Nur77’s cytoplasmic localization, whereas PI3K activation by insulin or AKT 
overexpression efficiently blocks TPA-induced Nur77 nuclear export, cytochrome c 
release, and apoptosis in gastric cancer cells [137]. In addition to Ser-351, the N-terminal 
region of Nur77, specifically residues 51-105, are also shown critical for AKT binding 
and phosphorylation-dependent regulation [137]. AKT’s inhibition of Nur77 has also 
been credited with mediating cisplatin-induced apoptosis in ovarian cancer cells [143]. 
 
 
The interplay of NR4A receptors and mTOR 
 
 AKT acts on multiple downstream proteins, including the mTOR kinase complex 
(mTORC1). The PI3K-AKT-mTOR axis could be considered to be a single pathway 
[130] in which AKT activates mTOR to control cell proliferation and growth in response 
to environmental stimuli by phosphorylating and inactivating the mTOR suppressors 
tuberous sclerosis protein 1 (TSC1) and TSC2 [144, 145]. Another upstream negative 
regulator of mTOR, liver kinase B1 (LKB1), activates AMP-activated protein kinase 
(AMPK) [146] to suppress the mTORC1 complex [147]. PTEN also negatively regulates 
mTOR by turning off PI3K-AKT signaling. The major effect of mTOR activation is 
increased protein synthesis, leading to increased expression of proteins involved in 
proliferation, survival, and angiogenesis [130]. 
 
 Nur77 indirectly activates mTOR signaling by attenuating AMPK signaling, and 
knockdown of Nur77 in non-small cell lung cancer cells decreased proliferation and 
enhanced apoptosis [148]. Whereas AMPKα phosphorylation was increased and mTOR 
phosphorylation decreased in that study, AKT phosphorylation status remained 
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unchanged, suggesting that the effect on mTOR occurs downstream of AKT. A previous 
microarray study by the same group demonstrated that sestrin-2 expression increased 
after knockdown of Nur77 [50]. Sestrin-2, a target gene of p53 [149], serves to activate 
AMPK signaling. Knowing that Nur77 has been shown to interact with and inhibit p53 
[150], the authors further showed that knockdown of Nur77 enhanced sestrin-2–mediated 
AMPK activation only in cells with wild-type p53. Further support for the role of Nur77 
in mTOR activation comes in a report demonstrating Nur77’s suppression of AMPK 
signaling [59], wherein knockdown or overexpression of Nur77 increased or decreased 
AMPK phosphorylation, respectively. This relationship was not seen in LKB1-null HeLa 
cells unless LKB1 was cotransfected with Nur77. Furthermore, Nur77-LBD interacts 
with and sequesters LKB1 in the nucleus, away from cytoplasmic AMPK, leading to 
decreased AMPK phosphorylation. A subsequent chemical screen found that the small 
molecule ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate (TMPA) enhanced 
AMPK phosphorylation by disrupting the Nur77-LKB1 interaction; this effect was not 
seen in LKB1-null cells, further confirming LKB1-dependency. These studies 
demonstrate interesting perspectives of Nur77 in which multiple signaling nodes are 
interconnected through Nur77, as PI3K-AKT suppresses the pro-apoptotic functions of 
Nur77 and Nur77 itself enhances downstream mTOR signaling to promote tumor 
progression, possibly in the context of LKB1 or p53. 
 
 
NR4A Receptors, Hypoxia, and Angiogenesis 
 
 
HIF-1 and cancer 
 
 The hypoxia-inducible factors (HIFs) are a family of transcription factors that 
mediate the balance of oxygen within tissues, having functions in multiple diseases, both 
in protective and pathogenic roles [151]. At normoxic conditions (i.e., normal oxygen 
levels), the HIF-1α subunit undergoes rapid proteolysis to maintain a low protein level, 
and the HIF-1β subunit remains at a relatively constant level [152, 153]. The HIF-1α 
subunit is maintained in its suppressed state by hydroxylation of specific prolyl residues 
[154, 155], which promotes an interaction with the von Hippel-Lindau tumor suppressor 
protein (pVHL) [156], a key protein responsible for targeting HIF-1α for proteasomal 
degradation by recruiting ubiquitin ligases [157]. The suppression of HIF-1α is released 
under hypoxic conditions (i.e., low oxygen levels) due to the unavailability of oxygen for 
the hydroxylation step, leading to loss of pVHL recognition of HIF-1α and an 
accumulation of HIF-1α protein. Additionally, a hydroxylation of HIF-1α by factor-
inhibiting HIF prevents binding of the coactivator p300 to the transactivation domain of 
HIF-1α, preventing its transactivation [158]. Once at sufficient levels, HIF-1α migrates to 
the nucleus where it forms a heterodimeric transcriptional complex with HIF-1β to 
regulate the expression of target genes, including those encoding erythropoietin (EPO) 
[159], vascular endothelial growth factor (VEGF) [160], and proteins involved in glucose 
uptake and metabolism [161-164]. The HIF-1 transcription factors are able to mediate 
key processes within hypoxic regions deep within newly established tumor sites to 
control the balance of oxygen consumption and oxygen delivery. HIF-1 effectively 
 19 
controls these processes by regulating the expression of hundreds of genes, many of 
which are involved in proliferation, metabolic adaption, and angiogenesis [165, 166], 
which are key hallmarks of cancer [167]. As summarized by Semenza [165], loss-of-
function and gain-of-function studies have revealed that the HIF-1 target gene products 
are tumor-promoting and, thus, increase proliferation, angiogenesis, and metastasis in 
multiple tumor models. Many primary tumors and metastases have increased HIF-1 
activation as indicated by increased staining of the HIF-1 protein in tissue samples when 
compared to adjacent normal tissue [168, 169], and its expression is associated with 
increased tumor vascularization and aggressiveness [170]. Increased HIF-1α expression 
and activity in cancer can be attributed to cancer-associated hypoxia, loss of tumor 
suppressor function (i.e. pVHL, p53 or PTEN), or contributions of growth factor or 
oncogene signaling (i.e. PI3K or MAPK), either through blocking degradation or 
enhancing synthesis of HIF-1α [166]. Patients with clear cell renal carcinoma and loss of 
pVHL have enhanced HIF-1α expression due to the decreased degradation of HIF-1α, 
defining pVHL as a tumor suppressor [171, 172]. 
 
 
The interplay of NR4A receptors and HIF-1 
 
 Hypoxia increases the expression of all three NR4A family members at both 
mRNA and protein levels in a HIF-1α–dependent manner [173-177]. HIF-1α, but not 
HIF-2α, can directly regulate Nur77 and Nor-1 expression by binding to hypoxia-
response elements in each gene’s promoter [173, 174, 176]. Additionally, the Nur77 
target gene proopiomelanocortin (POMC) is induced under hypoxic conditions through 
HIF-1α–dependent regulation of Nur77. Furthermore, Nur77 itself regulates HIF-1α, 
implicating this as a possible feedback mechanism in cancer progression. Expression of 
wild-type but not of dominant negative Nur77 can activate a hypoxia response element–
containing promoter, increasing nuclear localization of HIF-1α [174, 178]. Additionally, 
when examining this HIF-1 response to Nur77, the HIF-1 target gene VEGF increased at 
both the mRNA and protein levels, but HIF-1α increased at only the protein level and 
underwent attenuated ubiquitination [174, 178], suggesting stabilization of 
transcriptionally active HIF-1α by Nur77. Two reports have suggested different Nur77 
domains as being requirements for HIF-1α stabilization and transactivation, either 
through the N-terminal [174] or ligand-binding domain [178]. These domain-specific 
stabilizations of HIF-1α depend on different Nur77 protein interactions, although neither 
affects HIF-1α binding with pVHL. The N-terminal domain of Nur77 can block Mdm2 
from binding to and degrading HIF-1α and also leads to decreased Mdm2 expression 
[174]. However, another group demonstrated that Nur77-LBD can interact with the α-
domain of pVHL, forcing elongin C dissociation and blocking pVHL-mediated 
degradation of HIF-1α [178]. The fact that pVHL was required for Nur77-mediated 
stabilization indicates that pVHL serves as an adaptor protein to form a Nur77-pVHL-
HIF-1α complex. Interestingly, Nurr1 and Nor-1 positively regulate HIF-1α expression 
[175, 178], and HIF-1α–induced Nor-1 protects endothelial cells exposed to hypoxia, 
possibly by regulating cellular inhibitor of apoptosis 2 [176]. 
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 The regulation and function of Nur77 within hypoxic environments may be 
critical factors to consider and are addressed by a recent report showing crosstalk 
between Nur77 and β-catenin signaling during hypoxia [177], in which both were 
induced and required to positively regulate each other through transcription-independent 
mechanisms. Although Nur77 is typically considered to be a nuclear protein that 
regulates target gene expression in the context of cancer, hypoxia-induced Nur77 is 
highly expressed in the cytoplasm, and this localization is required for stabilization of β-
catenin [177]. This finding is similar to one in bladder cancer patients that indicated 
cytoplasmic Nurr1 level was correlated with poor prognosis, although other possible 
factors were not described [90]. Hypoxia can increase AKT phosphorylation in a Nur77-
dependent manner [177], presenting a unique regulatory mechanism, as Nur77 is 
phosphorylated by AKT to prevent its mitochondrial localization [137], thus preventing 
cell death and enhancing its pro-oncogenic functions. The feed-forward loop of Nur77 
and β-catenin promotes cell growth, migration, and invasion and alters epithelial-to-
mesenchymal transition (EMT) markers [177]. Together, these studies reveal that 
hypoxia affects both the level and function of NR4A receptors, which in turn play 
positive feedback roles that affect hypoxia-induced signaling. 
 
 
NR4A receptors as mediators of VEGF-induced angiogenesis 
 
 Given the reported roles of the NR4A receptors in hypoxia, a reasonable 
hypothesis might be that hypoxia-induced upregulation of NR4A receptors will positively 
regulate HIF-1α, thus increasing HIF-1–regulated genes and promoting survival, 
angiogenesis, and tumor promotion. The anti-metabolite 6-mercaptopurine (6-MP), 
known to increase NR4A transactivation through its AF-1 domain [179], induces the 
expression of all three NR4A members, HIF-1α, and VEGF and increases the stability, 
nuclear localization, and transactivation of HIF-1α protein in a Nur77-dependent manner 
[175]. The effects of 6-MP on NR4A and HIF-1α depend on p44/p42 ERK 
phosphorylation and can be abolished using a MEK inhibitor, a previously reported 
regulatory mechanism of Nur77 in hypoxia [174]. Furthermore, 6-MP enhances the HIF-
1α response in endothelial cells and promotes capillary tube formation [175], indicating 
that induction of Nur77 and its regulation of HIF-1α can promote angiogenesis. 
 
 One main mediator of angiogenesis is VEGF, which is induced by deoxycholic 
acid (DCA) through enhancing the expression of Nur77 in colon cancer cells [180]. 
VEGF stimulation of cells rapidly induces expression of all three NR4A members [181-
184], which mediate VEGF-induced effects on proliferation and angiogenesis. Similar to 
VEGF, Nur77 expression increases the proliferative rate of endothelial cells and protects 
cells from apoptosis [183], suggesting that VEGF exerts its effect by upregulating Nur77 
expression. Nur77 knockdown increases apoptosis, which cannot be rescued by addition 
of VEGF, further suggesting that Nur77 operates downstream of VEGF in this context. In 
addition, the effect of VEGF depends on Nur77, and both VEGF and Nur77 induce the 
expression of the cell cycle–related genes cyclin A, cyclin D1, proliferating cell nuclear 
antigen (PCNA), and E2F [183]. Inactivation of Nur77 reduces capillary tube formation, 
and mutants lacking the DNA-binding domain undergo no tube formation [183]. 
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Compared to wild-type mice, Nur77−/− mice form fewer xenograft tumors, with reduced 
angiogenesis within the tumors [183]. These data suggest that VEGF-induced 
angiogenesis is mediated through Nur77. 
 
 Induction of Nor-1 by VEGF has been attributed to VEGF receptor 2 (VEGFR-2), 
and its expression is modulated at the Nor-1 promoter through CBP [182]. Knockdown of 
Nor-1 in endothelial cells attenuates DNA synthesis and progression of cells into S-phase 
following VEGF stimulation, suggesting that Nor-1 mediates the effects of VEGF and 
confirming a previous finding of Nor-1’s role in vascular smooth muscle proliferation 
[185]. Similarly, VEGF-induced Nurr1 expression occurs rapidly, within 1 hour, and is 
mediated at the promoter level by NF-κB and CREB response elements [184]. Upon 
VEGF stimulation, CREB becomes phosphorylated and binds to the Nurr1 promoter, and 
this action can be blocked by inhibiting protein kinase D. Nurr1 knockdown can inhibit 
VEGF-mediated proliferation, migration, and in vivo angiogenesis [184]. These studies 
demonstrate that NR4A receptors are critical mediators of VEGF-mediated signaling. 
 
 
NR4A Receptors, p53, and Cell Death 
 
 
p53 and cancer 
 
 As the main arbitrator of determining cell cycle progression, DNA repair, and 
apoptosis, the tumor suppressor p53 is a central hub in regulating cell fate [186, 187]. In 
response to a stress stimulus, such as DNA damage, p53 is quickly induced. Induction of 
p53 typically occurs at the protein level through inhibition of p53 degradation, known as 
derepression, by the blocking of a critical ubiquitination by the E3 ligase Mdm2 and, 
ultimately, the enhancement of p53 protein stability. With increased p53 protein levels, 
the cell’s fate can now be regulated by tetramerization of p53 proteins and transcription 
of target genes. For example, p53 can drive the expression of cyclin-dependent kinase 
p21 [188, 189] and Gadd45 [190] to block cell-cycle progression, allowing the cell 
enough time to undergo DNA repair to correct any lesions. If the damage received proves 
to be too extensive, then p53 can initiate the cell death program through induction of 
genes such as Puma [191], Noxa [192], and Bax [193] to prevent the outgrowth of cells 
with damaged genomes. Additionally, p53 can execute the cell death program through 
DNA-binding–independent mechanisms by forming complexes with other signaling 
molecules such as B-cell lymphoma 2 (Bcl-2) at the mitochondrial membrane, which 
compromises the integrity of the outer mitochondrial membrane, resulting in cytochrome 
c release [194]. Through these multiple mechanisms of halting cell expansion, p53 serves 
as a critical tumor suppressor to prevent the formation of malignant lesions. 
 
 Since the discovery of p53, an overwhelming amount of reports have suggested 
that somatic p53 mutations occur in at least half of all cancers, with higher frequencies in 
certain malignancies, making it the most commonly mutated gene in cancer [195]. 
Mutations of p53, which commonly occur in its DNA-binding domain, serve to hijack its 
function as a tumor suppressor, making cells vulnerable to malignant transformation. 
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Also, because many p53 mutations occur in the DNA-binding domain, mutated p53, 
acting in a dominant-negative manner, is still able to form tetramers with wild-type p53 
protein to render them inactive [196]. Accumulating evidence also points to oncogenic 
functions of mutated p53 [197]. Additionally, in cancers with wild-type p53, the function 
of p53 can still be altered through overexpression of the negative regulator Mdm2 [198]. 
The importance of p53 in tumor suppression is evident in studies of p53 knockout mice in 
which all mice lacking p53 eventually succumb to disease, mostly due to sarcomas and 
lymphomas [199]. 
 
 
The interplay of NR4A receptors and p53 
 
 Both Nur77 and Nurr1 interact with p53 and regulate critical p53-dependent 
signaling, which could at least partially explain the oncogenic functions of NR4A 
receptors. On the heels of a finding that Nur77 could mediate Mdm2 degradation to 
promote HIF-1α stabilization [174] despite the lack of a Nur77-Mdm2 interaction, a 
direct interaction of Nur77 with p53 was demonstrated [150] that could explain this 
negative regulation of Mdm2. The Nur77-p53 interaction leads to a blockade of p53 
acetylation, resulting in loss of p53-dependent transactivation and subsequent decreased 
expression of the target genes Mdm2 and cyclin-dependent kinase inhibitor p21. 
Interestingly, Nur77 can enhance p53-dependent apoptosis with and without UV 
irradiation, suggesting non-genomic regulation within the Mdm2-p53 axis. Ubiquitination 
of p53 by Mdm2 is also obstructed by Nur77, enhancing its stability. The results of these 
studies suggest that the pool of available p53 protein might play an important role in its 
transcriptional regulation, protection from Mdm2-mediated destruction, and enhancement 
of apoptosis conferred by Nur77. More recent findings show that the Nur77-mediated 
enhancement of p53-dependent apoptosis is due to phosphorylation of Nur77 by DNA-
dependent protein kinase (DNA-PK) [200]. This phosphorylation of Nur77 enhances that 
of p53 by DNA-PK and, ultimately, increases the potential for induction of apoptosis 
upon DNA damage. 
 
 Similarly, Nurr1 interacts with p53 and inhibits p53-dependent apoptosis by 
inhibiting transactivation [95]. Nurr1 interacts with the C-terminal domain of p53 to 
attenuate doxorubicin-induced expression of the proapoptotic protein Bax, and cells 
lacking p53 do not exhibit doxorubicin resistance in the presence of Nurr1. The effects of 
Nurr1 on p53 are attributed to a reduction in the tetramerization of p53, which is required 
for its transcriptional activity. Although Nurr1 also has roles in DNA-PK–mediated DNA 
repair [201], the role of a Nurr1-p53 interaction in this process is unknown. Interestingly, 
a recent study found Nurr1 expression to be inversely correlated with p53 expression in 
primary breast cancer tissues [92]. The effects of p53 interaction with Nurr1, and Nur77 
likewise, have not been addressed, and it remains to be determined whether p53 can 
interfere with the oncogenic effects of the NR4A receptors through direct protein 
interactions or other signaling mechanisms. 
 
 NR4A receptors not only affect the immediate responses of p53 but also affect 
other downstream pathways in a p53-dependent context. One such pathway is the 
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AMPK-mTOR axis. As discussed in section 4.3, Nur77 can indirectly activate mTORC1 
signaling by inhibiting p53 [148]. In p53 wild-type cells, but not in p53-null cells, Nur77 
inhibited p53-mediated transactivation of the sestrin-2 promoter and subsequent 
expression of sestrin-2, a known target of p53 that inhibits mTOR signaling [149]. 
 
 
Nur77 in cell death 
 
 An intricate review by Moll and colleagues [202] draws parallels between p53 
and Nur77 as cell death mediators that act through the intrinsic cell death pathway. 
Regardless of the route in which p53 activates cell death (i.e., transcription-dependent or 
-independent), the ultimate outcome is a mitochondria-induced cell death either through 
p53 target genes such as PUMA or BAX or through direct interactions with other 
molecules such as Bcl-2 at the mitochondrial outer membrane. Similarly, increasing 
evidence points to multiple mechanisms of Nur77-mediated cell death through nuclear 
and cytosolic Nur77 functions (Figure 2-1). A well-characterized mechanism of Nur77-
mediated cell death is that in which Nur77 translocates from the nucleus to begin the 
apoptosis cascade, independently of transactivation, in response to certain death-inducing 
compounds [56, 203]. Nur77 heterodimerizes with retinoid X receptor (RXR) alpha and 
translocates from the nucleus to the cytosol, where the complex can target the 
mitochondria [204-206]. Bcl-2, a protein that is anti-apoptotic under most conditions, 
serves as a receptor on the mitochondrial outer membrane and is the downstream effector 
of Nur77 through an interaction with its ligand-binding domain [207]. Anti-apoptotic 
Bcl-2 is converted to a pro-apoptotic molecule through a conformational change of its 
Bcl-2 homology (BH) domains after Nur77 binding [207]. The conformational change 
exposes the buried pro-apoptotic BH3 domain of Bcl-2, resulting in a release of 
cytochrome c [141] and further activation of apoptosis. Deletion of the BH3 domain of 
Bcl-2 inhibits Nur77-mediated apoptosis. Another report suggests that Nur77 can mediate 
stress-induced apoptosis by targeting Bcl-2 at the endoplasmic reticulum (ER), leading to 
a release and depletion of ER calcium and activation of caspase-4 and -8 [208]. 
Therefore, cytosolic Nur77, by interacting with Bcl-2 either at the mitochondrial outer 
membrane or ER, is pro-apoptotic. 
 
 Although Nur77 exerts its pro-apoptotic effect largely through a translocation-
dependent mechanism, it also regulates specific target genes involved in cell cycle 
regulation, survival, and apoptosis. Therefore, small-molecule agonists [49-55] or 
antagonists [47-49] of Nur77 could be useful in modulating its transcription factor 
functions. One group has identified methylene-substituted diindolylmethanes (DIMs) as 
being agonists or antagonists of Nur77 and has shown that in vitro and in vivo treatment 
of colon, pancreatic, and bladder cancer cells with DIM-C-pPhOCH3 activates Nur77 
through its ligand-binding domain [49], leading to growth inhibition, cell cycle arrest, 
and/or cell death [49-53]. Treatment with DIM-C-pPhOCH3 causes a Nur77-dependent 
increase in TNF-related apoptosis-inducing ligand (TRAIL/TNFSF10), p21, and other 
genes, implicating DIM-C-pPhOCH3 in regulating the cell cycle and apoptosis [49-52] 
(Table 2-1). The DIM-C-pPhOCH3–mediated effects are independent of Nur77’s 
translocation to mitochondria, and Nur77 remains localized within the nucleus. TRAIL is  
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Table 2-1. Summary of gene expression changes after treatment with NR4A agonists or antagonists. 
 
  Compound  Detection     
Symbol Gene name Name Action  Direction Method NR4A-dependent? Direct? Cancer type Ref 
ATF3 Activating transcription factor 3 
DIM-C-
pPhOCH3 
Agonist  Increased M, G No n.d. Colon 51  M, G, P Yes; Nur77 n.d. Pancreatic 53 
ATF4 Activating transcription factor 4 
DIM-C-
pPhOH Antagonist  Increased P Yes; Nur77 n.d. Pancreatic 48 
BCL2 B-cell lymphoma 2 DIM-C-pPhOH Antagonist  Decreased P n.d. n.d. 
Pancreatic, 
Lung 47, 148 
BIRC5 
Baculoviral IAP 
repeat containing 5 
(Survivin) 
DIM-C-
pPhOH Antagonist  Decreased G, P, R, C Yes; Nur77 Yes 
Pancreatic, 
Lung 47, 148 
BRE 
Brain and 
reproductive organ-
expressed 
Cytosporone 
B Agonist  Decreased M, G, P, R, C Yes; Nur77 Yes Gastric 54 
CDKN1A 
Cyclin-dependent 
kinase inhibitor 1A 
(p21, Cip1) 
DIM-C-
pPhOCH3 
Agonist  Increased M, G, P, R, C Yes; Nur77 Yes Pancreatic, Bladder 50, 52, 53 
DIM-C-Ph Agonist  Increased G n.d. n.d. Pancreatic 52 
DDIT3 
DNA-damage-
inducible transcript 3 
(CHOP) 
DIM-C-
pPhOH Antagonist  Increased G, P Yes; Nur77 n.d. Pancreatic 48 
MYC 
V-Myc avian 
myelocytomatosis 
viral oncogene 
homolog (c-Myc) 
DIM-C-
pPhOH Antagonist  Decreased P n.d. n.d. Lung 148 
CTH 
Cystathionase 
(cystathionine 
gamma-lyase) 
DIM-C-
pPhOCH3 
Agonist 
 
Increased 
M, G No n.d. Colon 51 
 M, G Yes; Nur77 n.d. Bladder, Pancreatic 50, 53 
DUSP1 Dual specificity phosphatase 1 
DIM-C-
pPhOCH3 
Agonist  Increased M, G Yes; Nur77 n.d. Pancreatic 53 
EGFR Epidermal growth factor receptor 
DIM-C-
pPhOH Antagonist  Decreased P n.d. n.d. Lung 148 
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Table 2-1. (Continued). 
 
  Compound  Detection     
Symbol Gene name Name Action  Direction Method NR4A-dependent? Direct? Cancer type Ref 
FASLG 
Fas ligand (TNF 
superfamily, member 
6) 
DIM-C-
pPhOCH3 
Agonist  Increased P Yes; Nur77 n.d. Pancreatic 53 
GDF15 
Growth 
differentiation factor 
15 (NAG-1) 
DIM-C-
pPhOCH3 
Agonist  Increased M, G No n.d. Bladder, Pancreatic 50, 53 
PDCD1 Programmed cell death 1 
DIM-C-
pPhOCH3 
Agonist  Increased M, G Yes; Nur77 n.d. Colon 51 
NUPR1 
Nuclear protein, 
transcriptional 
regulator 1 (p8) 
DIM-C-
pPhOCH3 
Agonist  Increased M, G Yes; Nur77 n.d. Bladder 50 
SESN2 Sestrin 2 
DIM-C-
pPhOCH3 
Agonist  Increased M, G Yes; Nur77 n.d. Bladder 50 
DIM-C-
pPhOH Antagonist  Increased G, P, R, C Yes; Nur77 No Lung 148 
TNFSF10 
Tumor necrosis 
factor (ligand) 
superfamily, member 
10 (TRAIL) 
DIM-C-
pPhOCH3 
Agonist  Increased G, P Yes; Nur77 n.d. 
Pancreatic, 
Colon, 
Bladder 
50, 49, 51, 
53 
DIM-C-
pPhCH3 
Agonist  Increased P n.d. n.d. Pancreatic 49 
DIM-C-Ph Agonist  Increased G, P n.d. n.d. 
Pancreatic, 
Colon, 
Bladder 
50, 49, 51 
DIM-C-
pPhCl Agonist  Increased G, P Yes; Nurr1 n.d. Bladder 209 
TXNDC5 Thioredoxin domain containing 5 
DIM-C-
pPhOH Antagonist  Decreased M, G, P, R, C Yes; Nur77 Yes Pancreatic 48 
XBP1 X-box binding protein 1 
DIM-C-
pPhOH Antagonist  Increased P Yes; Nur77 n.d. Pancreatic 48 
 
Detection key: M = microarray, G = gene, P = protein, R = promoter reporter, C = chromatin IP; n.d. = not determined 
 26 
implicated in the extrinsic pathway of apoptosis, a cell death pathway that bypasses the 
intrinsic mitochondrial pathway, further supporting a translocation-independent 
mechanism. As expected, cleavage of caspase-8 is detected after treatment with DIM-C-
pPhOCH3 [49-51, 53]. Another compound in this series of DIM analogs, DIM-C-pPhOH, 
is described as a Nur77 antagonist, capable of inhibiting both basal and agonist-induced 
Nur77 transactivation through its N-terminal domain [47-49, 52]. Interestingly, DIM-C-
pPhOH can also inhibit in vitro and in vivo cancer cell growth and induce apoptosis [47-
49, 148], mimicking the effects seen after RNAi-mediated knockdown of Nur77, 
primarily through a Nur77-dependent regulation of target gene BIRC5/Survivin  
(Table 2-1). Nur77 knockdown or DIM-C-pPhOH treatment also cause morphological 
changes indicative of ER stress, which are accompanied by upregulation of ER stress 
genes and proteins (Table 2-1) and downregulation of the Nur77 target gene TXNDC5, a 
gene responsible for maintaining proper ROS levels [48]. The structure-dependent effects 
of C-DIMs on Nur77-regulated pro-apoptotic and anti-apoptotic genes, although not 
completely straightforward, are attributed to interactions with specific cofactors (i.e., 
p300) and other transcription factors (i.e., Sp1) [47, 52], but other genes are regulated 
through direct NBRE- and NuRE-binding sites. 
 
 Another DIM analog, DIM-C-pPhCl, was found to be a Nurr1-specific agonist 
[209]. This compound can inhibit TRAIL induction, apoptosis, and proliferation of 
bladder cancer cell lines, can block in vivo tumor growth, and can increase overall 
survival. These data suggest that Nurr1, similar to Nur77, may regulate both proliferative 
and survival genes (or death-inducing genes) depending on specific stimuli or structure-
dependent small-molecule features and that agonists or antagonists could be developed to 
regulate this orphan receptor. 
 
 The small-molecule natural product cytosporone B (Csn-B) and its analogs are 
also ligands for the Nur77 ligand-binding domain [54, 55]. Csn-B stimulates Nur77’s 
transcriptional activity through an interaction with Tyr-453 without affecting the activity 
of other NRs. A critical hydrogen bond is formed between a hydroxyl group of Csn-B 
(and its analogs) and Nur77 at Tyr-453 [54]. The series of analogs depend upon Nur77 in 
mediating apoptosis, which is induced by the translocation of Nur77 to the mitochondria 
after activation of the intrinsic pathway of apoptosis [55]. Csn-B and analogs suppress the 
expression of brain and reproductive organ–expressed protein (BRE), an anti-apoptotic 
protein. The promoter of BRE contains a binding site for Nur77, suggesting that 
modulation of nuclear Nur77 may suppress genes containing NBRE or NuRE in their 
promoter, possibly by recruiting corepressors (i.e., nuclear receptor co-repressor-1). 
Nur77 can also upregulate BRE in colon cancer cells after DCA treatment [180]. 
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NR4A, Wnt, and β-catenin 
 
 
Wnt and cancer 
 
 The roles of Wnt signaling in cancer have been previously reviewed [210, 211]. 
Wnt binds to and activates a Frizzled receptor, which then interacts with the intracellular 
Dishevelled to activate downstream events, including the canonical (i.e., β-catenin–
dependent) and non-canonical Wnt pathways [211]. In the canonical pathway, β-catenin 
accumulates within the cytoplasm and translocates to the nucleus, where it acts as a 
transcriptional coactivator of the TCF/LEF family of transcription factors. TCF/LEF then 
targets genes involved in cell proliferation, stem cell maintenance, and differentiation. 
These target genes include those of cyclin D1 and c-Myc, which are required for the 
transition from G1 to S phase in the cell cycle. In the absence of Wnt signaling, β-catenin 
is normally degraded by a complex of proteins including Axin, adenomatosis polyposis 
coli (APC), Glycogen synthase kinase 3β (GSK3β), and casein kinase 1α (CK1α). These 
proteins mediate phosphorylation of β-catenin, leading to ubiquitination and subsequent 
proteasomal degradation, thus preventing β-catenin from accumulating in the cytoplasm 
and performing its coactivator function. 
 
 Dysregulation of Wnt signaling has been linked to cancer development [210]. 
Wnt1 ligand is a proto-oncogene in a mouse model of breast cancer. Multiple signaling 
dysregulations lead to elevated β-catenin, which is strongly correlated with poor 
prognosis of breast cancer patients, and have been implicated in other cancers such as 
colorectal cancer, melanoma, prostate cancer, lung cancer, glioblastoma, esophageal 
cancer, ovarian cancer, and familial adenomatous polyposis. The initial consensus was 
that increased Wnt signaling always correlates with negative patient outcomes, however 
recent evidence shows otherwise. Enhanced Wnt signaling can either promote or inhibit 
cancer formation and progression, and this is strongly dependent on the type and stage of 
cancer. 
 
 
The interplay of NR4A receptors and Wnt signaling 
 
 Nuclear receptors, including the NR4A receptors, modulate the Wnt pathway 
[212, 213]. Nurr1 inhibits Wnt signaling by blocking β-catenin transactivation in both 
293F and MC3TC-E1 osteoblastic cells. A similar observation was made in U2OS 
osteosarcoma cells in which the NR4A receptors block the transcriptional activity of β-
catenin through a mechanism involving the DNA-binding domain of the NR4A receptors 
[213]. In addition, Nur77 promotes β-catenin degradation in the cytoplasm and inhibits 
tumor formation in vivo through transcriptional inhibition of the Wnt pathway [84, 214]. 
This finding would seem contradictory because Nur77 is overexpressed in most solid 
tumors; however, analysis of tissue samples from patients with colon cancer revealed that 
Nur77 is hyperphosphorylated by GSK-3β, which may impede its inhibition of the Wnt 
pathway [214]. Conversely, the NR4A receptors can indirectly increase β-catenin in 
melanoma cells. Nur77 targets CBP/p300-interacting transactivator 1 (CITED1) and 
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Nur77/Nurr1 targets Dishevelled-binding antagonist of beta-catenin 1 (DACT1), both of 
which are negative regulators of the Wnt pathway. CITED1 inhibits β-catenin 
transactivation, and DACT1 interacts with the Wnt activator Dishevelled to promote its 
degradation, leading to inhibition of the Wnt pathway [118]. Therefore, NR4A receptors 
inhibit CITED1 and DACT1 to increase Wnt activity. 
 
 Alternatively, the Wnt pathway can either upregulate or repress the NR4A 
receptors depending on the cellular context. In 293F cells, β-catenin and Nurr1 directly 
bind, disrupting an interaction with the corepressor Lef-1. This enables Nurr1 and β-
catenin to activate their transcriptional targets. This interaction is important for normal 
neuron development and the survival of dopaminergic neurons [84, 213]. Nur77 can also 
be upregulated upon the addition of the colon carcinogen DCA, which stabilizes β-
catenin and allows it to form a transcriptional complex with AP-1 that can then bind to 
the Nur77 promoter to enhance transcription of Nur77 [84, 213, 214]. Conversely, 
overexpression of β-catenin in U2OS and HeLa cells inhibits NR4A transcriptional 
activity through a mechanism involving the ligand-binding domain of the NR4A 
receptors [213]. 
 
 As discussed in section 5.2, a positive feedback loop between Nur77 and β-
catenin has been identified under hypoxic conditions in colorectal cancer cells [177]. β-
catenin induces Nur77 expression through HIF-1α. However, Nur77 can increase β-
catenin’s protein levels by increasing its half-life in the cytoplasm. Furthermore, the 
growth, migration, and invasion of colorectal cancer cells increase upon overexpression 
of β-catenin or Nur77, and these effects are further enhanced when β-catenin and Nur77 
are coexpressed. The authors of these findings argued that previous studies on the 
interaction between Nur77 and β-catenin are conflicting because of the normoxic 
conditions used in those studies and that it is, therefore, more realistic to perform these 
experiments under hypoxic conditions, which more closely mimic the environment of a 
tumor. Overall, it is clear that the tissue type and environmental conditions play an 
important role in how NR4A receptors interact with the Wnt pathway. 
 
 
CHD1L Oncogene and Nur77 
 
 
CHD1L and cancer 
 
 Chromodomain helicase/ATPase DNA binding protein 1-like, or CHD1L, is a 
member of the Snf2-like family of chromatin remodelers and modifiers [215]. Unlike 
other members of this family, CHD1L does not contain a chromodomain that recognizes 
methylated histone tails but, instead, harbors a macro domain containing a Poly (ADP-
ribose) (PAR)-binding element [216], which allows binding with Parp1 [217, 218]. 
Several groups have shown that CHD1L has macro domain–dependent ATPase activity 
in the presence of DNA and nucleosomes that is enhanced by Parp1 [217, 218]. CHD1L 
also interacts with proteins involved in DNA repair in a Parp1-dependent manner and is 
recruited to DNA damage break points through its macro domain [217, 218]. In addition 
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to its function in chromatin remodeling and DNA repair, CHD1L also has DNA-binding 
and transcription factor capabilities [219]. Confirmed target genes of CHD1L include 
ARHGEF9 [219], TCTP [220] and SPOCK1 [221]. 
 
 The CHD1L gene, also called ALC1 (Amplified in Liver Cancer 1), is an 
oncogene, residing in the frequent 1q21 amplicon found in some solid tumors [222], 
including hepatocellular carcinoma (HCC) [223, 224]; amplification of the 1q21 locus 
has been found in 58%-78% of HCC cases [224, 225]. Gain-of-function and loss-of-
function studies have confirmed the role of CHD1L as an oncogene, having the ability to 
enhance in vitro cell transformation and in vivo tumor formation and tumor size, which 
can be attributed to its ability to promote the G1/S phase transition [224]. In addition to 
its growth-promoting effects, CHD1L can protect cells from apoptosis [224] and 5-
fluorouracil [226]. Analyses of patient samples revealed that approximately 50% of 
patients with HCC have CHD1L overexpression [224, 226] and that 68% of metastatic 
tumor sites have higher levels of CHD1L than are found in the matching primary tumors 
[219]. Indeed, overexpression of CHD1L is associated with resistance to chemotherapy in 
patients with HCC [226]. Studies of CHD1L-transgenic mice further demonstrate the 
oncogenic ability of CHD1L, with about 25% of mice forming spontaneous tumors, 
including some cases of HCC [227]. 
 
 The effects of CHD1L on oncogenesis can be attributed to its transcription factor 
function and target genes. The first target gene identified for CHD1L was ARHGEF9 
[219], a guanine nucleotide exchange factor that activates Cdc42, which is a GTPase 
involved in epithelial-to-mesenchymal transition (EMT) and metastasis [228]. Indeed, 
CHD1L overexpression can induce an AHGEF9-Cdc42–dependent EMT, resulting in 
increased in vivo tumor invasiveness and metastasis. Target gene TCTP is overexpressed 
in about 40% of HCC patient samples and is associated with advanced tumor stage; its 
overexpression increases in vivo tumor formation via faster mitotic exit and cell division 
[220]. Similarly, CHD1L target gene SPOCK1 is associated with clinical stage and 
metastasis and can protect cells from staurosporine-induced apoptosis in an AKT-
dependent manner [221]. 
 
 
The interplay of Nur77 and CHD1L 
 
 Recent evidence demonstrates that Nur77 interacts directly with the CHD1L 
protein [229]. The C-terminal macro domain of CHD1L interacts with Nur77, inhibiting 
its nuclear-to-mitochondrial translocation and subsequent induction of apoptosis. CHD1L 
expression in a panel of HCC cell lines negatively correlates with induction of apoptosis 
following staurosporine treatment, further supporting CHD1L’s role as an inhibitor of 
apoptosis and a potential mediator of drug resistance. It remains to be determined which 
residues of Nur77 are critical in the interaction with CHD1L and whether this interaction 
prevents binding of other proteins, such as RXR, or specific post-translational 
modifications of Nur77. Additionally, CHD1L is involved in chromatin remodeling and 
DNA repair [217, 218], which is mediated by its C-terminal macro domain through 
interactions with Ku70 and DNA-dependent protein kinase, catalytic subunit (DNA-
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PKcs). Given that Nur77 interacts with Ku80 to suppress DNA repair [200], it is 
plausible that a Nur77-CHD1L interaction could also repress chromatin remodeling and 
subsequent DNA repair, making the interaction mutually inhibitory. Also of interest is 
that CHD1L-mediated expression of SPOCK1 can activate AKT to maintain 
mitochondrial membrane potential, which prevents cytochrome c release and apoptosis, 
all of which is blocked by pretreatment with an AKT1 inhibitor [221]. This scenario 
raises the possibility that CHD1L might inhibit Nur77 translocation through both a direct 
protein-protein interaction and through activation of AKT, which is known to be 
inhibitory to Nur77’s mitochondrial association [137]. The regulation of Nur77 by 
CHD1L might offer a useful therapeutic avenue in which a small molecule could be 
developed to disrupt this interaction, allowing Nur77 to become fully functional in the 
cell death program. 
 
 
Concluding Remarks 
 
 In summary, the NR4A family, represented by three highly homologous orphan 
receptors, plays multiple roles in cancer, with most studies highlighting the pro-
oncogenic functions of Nur77 and Nurr1. In addition, Nur77 and Nor-1 have been 
characterized as being tumor suppressors in AML, likely due to their regulation of 
apoptosis in hematopoietic cells. This finding, in combination with other confounding 
results, as indicated by overexpression or downregulation in cancer cell lines and patient 
samples, shows the need to determine the cellular context in which the NR4A receptors 
contribute to oncogenesis or tumor suppression. It appears that multiple nuances can 
determine the role of NR4As in cancer, including but not limited to cell and tissue type, 
subcellular localization, external stimuli, protein-protein interactions, and post-
translational modifications. 
 
 The NR4A family is intertwined with many relevant cancer signaling pathways, 
which likely explains the dysregulated expression of these NRs in cancer, as well as their 
functions in tumorigenic hallmarks, including proliferation and survival (Figure 2-2). As 
an emerging research topic, it is highly likely that microRNAs are able to regulate the 
expression of NR4As in cancer, making their regulation and function much more 
interesting yet complex. Determining the contributions of microRNAs to NR4A 
regulation would provide further insight into NR4A dysregulation, as it is likely that a 
deleted or silenced tumor suppressor–like microRNA could target NR4A, explaining the 
general consensus of NR4A overexpression. Restoration of microRNA expression by 
using chemically modified and/or lipid-encapsulated mimics could lead to suppressed 
NR4A expression, ultimately reducing proliferation and inducing apoptosis. 
 
 Lastly, due to its dual functions in cell proliferation and death, Nur77 remains a 
unique drug target that several groups are targeting using small molecule approaches. 
One promising approach using small molecules would be to target the Nur77-CHD1L 
interface in hepatocellular carcinoma with 1q21 amplification to release nuclear-retained 
Nur77 from CHD1L; presumably, this type of small molecule could be used in  
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Figure 2-2. The NR4A family and key signaling pathways regulate each other. 
Both the expression and function of the NR4A members are mediated by activation or 
inhibition of multiple signaling pathways. Growth factor signaling upregulates the 
expression and nuclear localization of NR4A members and inhibits NR4A nuclear export 
and cell death. Additionally, NR4A members can either positively regulate oncogenic 
signaling pathways (i.e., HIF, β-catenin, mTOR) or overcome tumor suppressor signaling 
(i.e., pVHL, p53, LKB1). 
 
  
 32 
combination with compounds that induce Nur77 nuclear export to yield a higher 
apoptotic response. 
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CHAPTER 3.    THE ORPHAN NUCLEAR RECEPTOR NR4A2 IS PART OF A 
P53–MICRORNA-34 NETWORK 
 
 
Introduction 
 
 The nuclear receptor (NR) superfamily is a group of ligand-regulated transcription 
factors that control specific gene activity. NRs are thus important drug targets [9, 15]. 
The 48 members of the human NR family share a common modular structure that 
includes an N-terminal domain containing an activation function 1 (AF-1) region, a 
DNA-binding domain (DBD), a hinge region, and a C-terminal ligand-binding domain 
(LBD) that also harbors an AF-2 domain. NR subfamily 4 group A (NR4A) consists of 
three highly homologous NRs, including NR4A2 (also called Nurr1, NOT, TINUR, or 
NGFI-Bβ), that are characterized as immediate-early genes induced by mitogens, growth 
factors, and other stimuli [78]. The NR4A receptors have been implicated as having roles 
in multiple tissues and diseases, including cancer [86], and their expression and function 
are associated with various oncogene and tumor suppressor pathways [45]. 
 
 NR4A2 is involved in cancer progression through a mechanism that has yet to be 
fully described. Most research indicates that NR4A2 has an oncogenic-like role, as it 
mediates cell proliferation, survival, transformation, invasion, and migration [88, 90, 92, 
118, 209]. NR4A2 is highly expressed in squamous cell carcinoma (SCC), as compared 
to normal patient tissues, and prostaglandin-mediated induction of NR4A2 expression in 
SCC leads to increased resistance to 5-fluorouracil (5-FU) [93]. The effects of NR4A2 on 
chemoresistance are also seen in colorectal cancers [94, 230], and high expression of 
NR4A2 predicts a poor outcome for gastric cancer patients receiving 5-FU therapy [231]. 
NR4A2 may mediate these effects through a previously described NR4A2-p53 
interaction that serves to suppress p53 transactivation, thereby protecting cells from p53-
induced apoptosis [95]. Another NR4A family member, NR4A1 (also called Nur77, TR3, 
or NGFI-Bα), has also been implicated in p53 suppression [150]. 
 
 As the main arbiter of cell cycle progression, DNA repair, and apoptosis, p53 is a 
central hub for regulating tumor suppression. These effects are mediated through p53 
target genes, which include the microRNA-34 (miR-34) family [70, 71, 75, 232]. 
MicroRNAs (miRNAs) are small, endogenous, noncoding RNAs that help regulate target 
gene networks by binding complementarily to the 3′ untranslated regions (UTRs) of 
target genes to degrade or prevent their translation into proteins [67]. The miR-34 family, 
which consists of three isoforms (miR-34a, miR-34b, and miR-34c) encoded by two p53 
direct transcriptional target genes (mir-34a and mir-34b/c), is considered to be partly 
responsible for carrying out p53’s tumor suppressive function by targeting the 3′ UTRs of 
genes that are critical to the cell cycle and survival, such as BCL2, cyclins, cyclin-
dependent kinases (CDKs), and MYCN [75, 233]. In mice, mir-34a is expressed at higher 
levels than mir-34b/c, except in lung tissues, where mir-34b/c is dominantly expressed 
[75]. Although miR-34 is dispensable for p53 tumor suppression [234], it is critical for 
enhancing p53 stability and activity through miR-34–mediated suppression of negative 
regulators of p53, such as Sirt1 [235] and Hdm4 [236]. The miR-34 isoforms have been 
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clinically characterized as tumor suppressors in multiple cancer types, often independent 
of p53 mutation, as in neuroblastoma, where mir-34a is commonly deleted [73, 74], or in 
other cancers characterized by epigenetic silencing of miR-34 [237, 238]. 
 
 Recently, miR-132 was reported to target mouse Nr4a2 [239, 240]; the first 
characterization of an miRNA targeting an NR4A member. In this study, to determine 
whether human NR4A2 is regulated by miRNAs and investigate its oncogenic-like role, 
we used an miRNA screening approach to identify cancer-relevant posttranscriptional 
regulatory networks of NR4A2, a subject that has not been fully explored. We identified 
miR-34 as a direct regulator of NR4A2 through a specific sequence in its 3′ UTR. 
Furthermore, we determined that elevated miR-34 levels, resulting from exogenous 
overexpression or endogenous induction in a p53-dependent manner, decreased the levels 
of NR4A2. Corroborating the reported NR4A2-mediated inhibition of p53 [95], we found 
that overexpression of NR4A2 inhibited the ability of p53 to activate its target genes, 
including mir-34a. Lastly, overexpression of NR4A2 attenuated the sensitivity of cells to 
the p53 activator Nutlin-3a. These data are consistent with previous findings and, for the 
first time, identify miR-34 as a direct negative regulator of NR4A2. Together, they reveal 
a novel regulatory network linking p53, miR-34, and NR4A2, in which p53 can 
overcome its inhibition by endogenous NR4A2 through upregulating miR-34. 
 
 
Results 
 
 
Identification of miRNAs directly targeting the 3ʹ UTR of NR4A2 
 
 Increased NR4A2 expression in cancer has been characterized as resulting from 
cell signaling events [45], but miRNA-mediated regulation of NR4A2 in cancer has 
hitherto been unexplored. To identify putative miRNAs capable of regulating NR4A2 
through its 3′ UTR, we assessed the effects of 75 cancer-relevant miRNAs by using a 
luciferase reporter system (Figure 3-1a). Precursor miRNAs selected from an established 
library [241] (Table A-1) or an miRNA negative control (pSIF) were cotransfected with 
the NR4A2 3′ UTR reporter plasmid (WT 3UTR) in 293T cells. We observed that several 
miRNAs, including miR-34c, were capable of decreasing the luminescence reporter 
signal to a significantly greater extent than was miR-132, an miRNA that targets Nr4a2 
[239, 240] (log2 fold changes of −0.47521 and –0.29685, respectively; P ≤ 0.0001 and 
P = 0.0086, respectively) (Figure 3-1b and Table 3-1). This suggested that miR-34c was 
a modulator of NR4A2 through its 3′ UTR. 
 
 By using three different miRNA prediction algorithm tools (TargetScan [242], 
miRanda [243], and PicTar [244]), we identified NR4A2 as a predicted target of the miR-
34 family (Table 3-1), further suggesting that this family of miRNAs were regulators of 
NR4A2. As expected, miR-132 was also predicted to target NR4A2. To corroborate the 
findings from “first-generation” prediction tools, we used the CoMeTa interactive 
database [245], which integrates thousands of publicly available gene-expression datasets 
with the assumption that the predicted targets of an miRNA will be coexpressed with 
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Figure 3-1. Screening for miRNAs that directly target the 3′ UTR of NR4A2.  
(a) A reporter plasmid containing the 3′ UTR of NR4A2 downstream from a firefly 
luciferase (Fluc) gene was used to identify miRNAs that putatively regulate NR4A2, 
relative to an internal Renilla luciferase (Rluc) control gene. (b) 293T cells were 
transfected with the NR4A2 3′ UTR (WT 3UTR) reporter construct for 24 h. Transfected 
cells were reseeded in 96-well plates and reverse transfected with 75 individual cancer-
relevant miRNAs. After 48 h of transfection, a Dual-Glo luciferase assay was performed, 
the ratio of Fluc/Rluc was calculated, and the log2 fold change was determined for each 
miRNA (n = 3), relative to a transfection control (pSIF, n = 9), and presented as a 
waterfall plot. The Fluc/Rluc value for pSIF was set as 1. Statistical significance was 
calculated using a one-way ANOVA and Dunnett’s test for multiple comparisons 
between pSIF and the indicated miRNAs. (c) A schematic of the predicted miR-34 seed 
region in the NR4A2 3′ UTR (WT 3UTR). This predicted miR-34 binding site in the 
NR4A2 3′ UTR was mutated, and the resulting loss of complementarity is shown (34mut). 
(d) WT 3UTR or 34mut reporter constructs were cotransfected with pSIF or the indicated 
miR-34 isoforms into HCT116 colorectal carcinoma cells for 72 h, after which a Dual-
Glo luciferase assay was performed. The fold change of the Fluc/Rluc ratio with respect 
to pSIF was calculated (the Fluc/Rluc value of pSIF for each reporter transfection group 
was set as 1), and the statistical significance of the relation between pSIF and miR-34a or 
miR-34c was determined using a two-way ANOVA and Tukey’s test for multiple 
comparisons (****, P ≤ 0.0001; n.s., P > 0.05). Statistically significant changes in WT 
3UTR and 34mut for each miRNA transfection are indicated by #### (P ≤ 0.0001). 
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Table 3-1. MicroRNAs that putatively regulate NR4A2 through its 3ʹ UTR. 
 
Rank miRNA ID Log2 fold change P-value TargetScan miRanda PicTar 
Other predicted 
NR4A genes Other targets 
1 hsa-miR-335 −0.47549 ± 0.0223 < 0.0001 No No No NR4A3 
BCL2L2, SOX4, RB1, 
RUNX2 
2 hsa-miR-34c −0.4752 ± 0.1028 < 0.0001 Yes Yes Yes --- 
BCL2, CCND1, CDK4/6, 
FRA1, MET, MYC, MYCN, 
SIRT1, SNAI1 
3 hsa-miR-144 −0.44443 ± 0.0696 < 0.0001 No No No NR4A3 NOTCH1, PTEN, TGFB1 
4 hsa-miR-214 −0.37908 ± 0.0942 0.0002 No Yes Yes NR4A1 
BCL2L2, EZH2, PTEN, 
TWIST1 
5 hsa-miR-191 −0.37123 ± 0.1471 0.0002 No No No --- CDK6, SOX4 
6 hsa-miR-15a −0.36165 ± 0.0343 0.0004 No No No NR4A1, NR4A3 
BCL2, CCND1, CCND2, 
CCNE1, CRKL, VEGFA 
7 hsa-miR-155 −0.36052 ± 0.0926 0.0004 No No No NR4A3 
APC, FOXO3, MLH1, 
RUNX2, SMAD1, SMAD2, 
SMAD5 
8 hsa-miR-20a −0.35512 ± 0.0296 0.0005 Yes Yes Yes NR4A3 
CCND1, CDKN1A, E2F1, 
HIF1A, KIT, PTEN 
9 hsa-miR-25 −0.35227 ± 0.128 0.0006 No No No NR4A3 
BCL2L11, CDH1, EZH2, 
MDM2, TP53 
17 hsa-miR-132 −0.296850 ± 0.1684 0.0086 Yes Yes Yes --- 
CDKN1A, NR4A2, RB1, 
SIRT1 
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each other. The authors noted that targets falling within the top 50th percentile of the 
CoMeTa analysis “co-rank” list for putative miRNA targets are highly predictive, based 
on previous dataset validation. CoMeTa analysis indicates that NR4A2 falls within the top 
40.568 and 39.182 percentiles for miR-34a and miR-34c-5p, respectively. By using the 
prediction algorithms, we identified a predicted miRNA recognition element 
complementary to the miR-34 seed region in the 3′ UTR of NR4A2 and mutated this 
sequence to disrupt the complementarity in order to determine if there was direct 
regulation by miR-34 at this specific site (Figure 3-1c). The wild-type 3′ UTR (WT 
3UTR) reporter signal was effectively suppressed by cotransfection of miR-34a or miR-
34c (52% and 62% of the control level, respectively; P ≤ 0.0001 for all) (Figure 3-1d). 
The effect of miR-34a or miR-34c, compared to that of the control, was not significant 
when the miRNA was cotransfected with the 3′ UTR containing the seed-region mutation 
(34mut). Mutation of this predicted seed region was able to rescue the attenuation of the 
luminescence signal by miR-34a or miR-34c (Figure 3-1d), increasing the signal from 
52% to 99% and from 62% to 111% of the control level, respectively (P ≤ 0.0001 for all). 
These data indicate that miR-34 can target NR4A2 at a specific seed complementarity 
region within its 3′ UTR. Furthermore, by analyzing a dataset from 97 patient samples 
with rectum adenocarcinoma, we found that the expression of NR4A2 and miR-34a was 
inversely correlated to a similar extent as other miR-34 targets AXL [246] and SIRT1 
[235] (Figures A-1 and A-2). The read counts for miR-34b and miR-34c in this dataset 
were very low (data not shown), which is consistent with the known expression patterns 
of mir-34b/c primarily in lung tissues[75], making correlation analyses for the mir-34b/c 
isoforms not suitable. 
 
 
miR-34 regulates endogenous NR4A2 levels 
 
 We next determined the in vitro effect of miR-34 on endogenous NR4A2 mRNA 
and protein levels through the use of miRNA mimics. Mature miR-34a-5p or miR-34c-5p 
mimics or a control (CmiR) were overexpressed in HCT116TP53−/− (KO) or HCT116 
wild-type (WT) isogenic cell lines to assess the direct effects of forced miRNA 
expression on NR4A2. Transfection of mature miR-34 mimics increased the expression of 
each miRNA (Figure 3-2a, b). Transfection of miR-34a-5p slightly increased miR-34c-
5p expression, probably because of specificity differences in the stem loop primers 
caused by the approximately 80% sequence homology of the two miR-34 isoforms. 
Overexpression of the miR-34a-5p mimic reduced the endogenous NR4A2 expression to 
59% and 64% of the control level in KO and WT cells, respectively, by 12 h post-
transfection, whereas overexpression of the miR-34c-5p mimic reduced the NR4A2 
expression to 71% and 66% of the control level in KO and WT cells, respectively 
(Figure 3-2c), and this effect was independent of p53 status. At 24 h post-transfection, 
the effect of the miR-34 mimics on NR4A2 levels in HCT116 with wild-type p53 was no 
longer obvious, by comparison to the control. Additionally, the transfection of miR-34 
mimics led to increased expression of the p53 target gene CDKN1A/p21 (Figure 3-2d), 
increased p53 protein expression and acetylation, and subsequent p21 protein levels 
(Figure A-3) in wild-type HCT116 cells. The observation that increased levels of miR-34 
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Figure 3-2. miRNA-34 downregulates endogenous NR4A2.  
Mature miR-34a and miR-34c mimics (10 nM) were transfected into HCT116TP53−/− 
(KO) or HCT116 wild-type (WT) cells for 12 or 24 h. Expression of hsa-miR-34a-5p (a), 
hsa-miR-34c-5p (b), NR4A2 (c), and CDKN1A (d) was determined using TaqMan qPCR 
probes. Mature miRNA expression was normalized to RNU6B, and NR4A2 and CDKN1A 
were normalized to GAPDH. The value for the CmiR-transfected KO cells at each time 
point was set as 1. The statistical significance of the results of miR-34 transfections, 
compared to those of the control, in each cell line for each time point was calculated 
using a two-way ANOVA and Dunnett’s test for multiple comparisons.****, P ≤ 0.0001; 
*, P ≤ 0.05. (e) Whole-cell lysates (45 μg) from HCT116TP53–/– (KO) and HCT116 wild-
type (WT) cells transfected for 48 h with control (CmiR), miR-34a (34a), or miR-34c 
(34c) mimics (10 nM) were assessed for expression of NR4A2 and β-actin protein by 
performing Western blotting analysis. 
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led to enhanced p53 protein expression and activity probably reflects the known 
suppressive function of miR-34 on negative regulators of p53 protein stability  
(Figure A-3) [235, 236], though TP53 gene expression (in terms of mRNA levels) was 
also slightly increased by the miR-34 mimics (Figure A-3). The slight but significant 
increase in TP53 expression induced by the miR-34 mimics is consistent with the 
observation that the levels of NR4A2 correlate inversely with that of TP53 gene 
expression, as discussed later. After 48 h of miR-34 mimic overexpression in HCT116 
cells, the protein levels of NR4A2 (Figure 3-2e) and another miR-34 target, Sirt1 
(Figure A-3), were reduced in both KO and WT cells. Additionally, the effect of mature 
miR-34 mimics on NR4A2 expression was assessed in another colorectal cancer cell line, 
RKO, with similar results observed on CDKN1A and NR4A2 expression (Figure A-4). 
These data demonstrate that exogenous overexpression of a mature miR-34 decreases the 
levels of endogenous NR4A2 at both mRNA and protein level, regardless of the p53 
status. The differential effect of exogenous miR-34 mimic on endogenous NR4A2 may be 
attributable to the different levels of endogenous NR4A2 mRNA in TP53+/+ and 
TP53−/− cells, although NR4A2 protein expression was substantially decreased in both 
TP53-isogenic backgrounds in response to exogenous miR-34 mimic. 
 
 
p53 activation suppresses endogenous NR4A2 levels 
 
 As mir-34a is a direct transcriptional target of p53 [71, 232], we next sought to 
determine if NR4A2 expression was regulated by endogenous miR-34a in a p53-
dependent manner. We treated cells with a chemical activator of p53, Nutlin-3a [247], 
and confirmed that the p53 protein level increased after the treatment in cells expressing 
wild-type p53 (WT) but not in p53-deficient (KO) cells (Figure 3-3a). As expected, the 
expression of transcriptional targets of p53, CDKN1A/p21 and BBC3/Puma, was also 
induced in a p53-dependent manner (Figure 3-3a). HCT116CDKN1A−/− and HCT116BBC3−/− 
cells were used to demonstrate that Nutlin-3a acts upstream of CDKN1A/p21 and 
BBC3/Puma through p53 (Figure 3-3a). We also found increased expression of 
CDKN1A/p21 and mir-34a in cells expressing wild-type p53 (Figure 3-3b, c), 
accompanied by decreased NR4A2 transcript levels after 48 h of treatment with Nutlin-3a 
(Figure 3-3d). The NR4A family, including NR4A2, are immediate-early responsive 
genes that are inducible by many external stimuli [78], and at an earlier time point (24 h), 
the levels of NR4A2 mRNA were actually increased by Nutlin-3a (Figure 3-3d). In 
agreement with mRNA expression, Nutlin-3a treatment for 48 h also caused a decrease in 
the NR4A2 protein expression in WT cells, but not in KO cells (Figure 3-3e), further 
demonstrating the p53 requirement for Nutlin-3a?induced NR4A2 decrease. In addition 
to NR4A2, Nutlin-3a was also capable of decreasing the protein expression of Sirt1 
(Figure 3-3e), a known target of miR-34 [235], suggesting that p53 activation can 
regulate other downstream factors, possibly through miR-34. We confirmed these results 
in other colorectal cell lines (RKO and SW48) that are isogenic for TP53  
(Figures A-5 and A-6). These data indicate that p53 activation can induce the expression 
of mir-34a, while also decreasing the endogenous levels of NR4A2 and another known  
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Figure 3-3. Nutlin-3a activation of p53 decreases endogenous NR4A2.  
(a) HCT116 wild-type (WT), HCT116CDKN1A−/− (p21KO), HCT116TP53−/− (p53KO), and 
HCT116BBC3−/− (PumaKO) isogenic cell lines were treated for 48 h with 10 μM of 
Nutlin-3a or vehicle control (DMSO). Whole-cell lysates (40 μg) were assessed for 
expression of p53, p21, Puma, and β-actin by SDS-PAGE gel electrophoresis. (b–d) 
HCT116TP53–/– (KO) and HCT116 wild-type (WT) cells were treated with vehicle control 
(DMSO) or Nutlin-3a (5 or 10 μM) for 24 or 48 h. Expression of CDKN1A (b), mir-34a 
(c), and NR4A2 (d) was determined using TaqMan qPCR probes (normalized to 
GAPDH). The value for DMSO-treated KO cells at each time point was set as 1. The 
statistical significance of the results obtained with Nutlin-3a treatments, compared to 
those obtained with DMSO, in each cell line for each time point was calculated using a 
two-way ANOVA and Dunnett’s test for multiple comparisons. ****, P ≤ 0.0001; ***, 
P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05. (e) Whole-cell lysates (45 μg) from HCT116TP53–/– 
(p53KO) and HCT116 wild-type (WT) cells treated for 48 h with DMSO (0 μM) or 
Nutlin-3a (5 or 10 μM) were assessed for expression of indicated proteins by performing 
Western blotting analysis. 
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target of miR-34 (Sirt1). These results are consistent with the observation that the levels 
of miR-34 and NR4A2 are inversely correlated. 
 
 
Overexpression of NR4A2 suppresses p53 activation 
 
 It was previously reported that NR4A2 suppressed the transcriptional activity of 
p53 in the presence or absence of doxorubicin [95]. We sought to determine the effects of 
NR4A2 overexpression on the induction of p53 activation by Nutlin-3a. HCT116 cells 
were transduced with lentivirus expressing empty vector control (EV) or 3xFlag-NR4A2, 
and overexpression of NR4A2 was confirmed (Figure 3-4a). The EV- or 3xFlag-NR4A2–
transduced cells were treated with Nutlin-3a to determine the effect on p53 downstream 
target genes. Upon Nutlin-3a treatment, overexpression of NR4A2 led to a significant 
attenuation of the p53-induced expression of the target genes mir-34a and CDKN1A/p21 
(Figure 3-4b, c). To assess the effect of NR4A2 on the binding of p53 to target gene 
promoters, we performed a chromatin immunoprecipitation (ChIP) assay. As shown in 
Figure A-7, NR4A2 did not decrease p53 occupancy at the target gene promoters [248, 
249], suggesting that another mechanism is responsible for the inhibitory effect of 
NR4A2 on p53. However, HCT116 cells overexpressing NR4A2 had diminished levels 
of p53 mRNA and protein (Figure 3-4d, e and Figure A-7). These data demonstrate that 
NR4A2 exerts inhibitory effects on the levels of p53 and its transcriptional target genes, 
which is consistent with previously reported results [95] and suggests that the attenuation 
of p53 mRNA and protein levels, but not of p53 binding to target gene promoters, 
probably contributes to such inhibitory effects. 
 
 
Knockdown of NR4A2 enhances p53 activation 
 
 To further confirm the inhibitory effect of NR4A2 on p53 transcriptional activity, 
we investigated the effects of reduced endogenous NR4A2 levels on Nutlin-3a–induced 
p53 transcriptional target gene expression. HCT116 cells were transfected with 
nontargeting control (NT) or siRNA targeting NR4A2 (siNR4A2), and knockdown of 
NR4A2 was confirmed (Figure 3-5a). After 48 h of siRNA-mediated knockdown, the 
cells were treated with Nutlin-3a for an additional 24 h to determine the effects of NR4A2 
knockdown on p53 target gene expression. We found that knocking down NR4A2 caused 
an enhancement of Nutlin-3a–induced expression of CDKN1A/p21, MDM2, and mir-34a 
(Figure 3-5b–d). Consistent with the inhibitory effect of overexpressed NR4A2 on p53 
gene expression (Figure 3-4d), knocking down NR4A2 led to an increase in TP53/p53 
gene expression for both the DMSO- and Nutlin-3a–treated groups (Figure 3-5e). 
Together, these data further suggest that NR4A2 can suppress p53 transcriptional 
activity, at least in part, by inhibiting the expression of p53 itself. 
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Figure 3-4. NR4A2 overexpression suppresses p53 activation. 
HCT116 cells were transduced for 16 h overnight with lentivirus expressing empty vector 
(EV) or 3xFlag-NR4A2 (NR4A2). The cell medium was then changed and the cells 
remained in culture for a total of 48 h. The cells were then reseeded and treated with 
vehicle (DMSO) or Nutlin-3a (5 or 10 μM) for 24 or 48 h. Expression of NR4A2 (a), mir-
34a (b), CDKN1A (c), and TP53 (d) was determined using TaqMan qPCR probes 
(normalized to GAPDH). The value for DMSO-treated EV at each time point was set as 
1. The statistical significance of the difference between the results with EV and NR4A2 
for each treatment was determined for each time point by using a two-way ANOVA with 
Sidak’s multiple comparisons test. ####, P ≤ 0.0001; ###, P ≤ 0.001; ##, P ≤ 0.01; #, 
P ≤ 0.05. (e) Whole-cell lysates from HCT116TP53–/– (KO) and HCT116 wild-type (WT) 
cells transduced with lentivirus expressing EV or 3xFlag-NR4A2 (F-NR4A2) were 
assessed for expression of Flag (indicating NR4A2), p53, and Gapdh protein by 
performing SDS-PAGE gel electrophoresis. Relative p53 expression was determined 
using Odyssey Image Studio to calculate the ratio of p53 to Gapdh protein band density 
(displayed at the bottom of the gel). The ratio for EV in WT cells was set as 1.0. 
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Figure 3-5. Knockdown of NR4A2 enhances p53 activation.  
HCT116 cells were transfected for 24 h with nontargeting control (NT) or siRNA 
targeting NR4A2 (siNR4A2). The culture medium was then changed, and the cells 
remained in culture for a total of 48 h. The cells were then treated with vehicle (DMSO) 
or Nutlin-3a (10 μM) for 24 h. Expression of NR4A2 (a), CDKN1A (b), MDM2 (c), mir-
34a (d), and TP53 (e) was determined using TaqMan qPCR probes (normalized to 
GAPDH). The value for DMSO-treated NT was set as 1. The statistical significance of 
the results was determined using a two-way ANOVA with Tukey’s multiple comparison 
test. The significance of the differences within each transfection group between 
transfection groups (####, P ≤ 0.0001; ###, P ≤ 0.001; ##, P ≤ 0.01) is represented. 
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Overexpression of NR4A2 attenuates Nutlin-3a sensitivity 
 
 We next examined the cellular effects of NR4A2-mediated suppression of p53 
after Nutlin-3a treatment. HCT116 cells transduced for 48 h with lentivirus expressing 
empty vector control (EV) or 3xFlag-NR4A2 were plated in normal growth medium, and 
the cell proliferation was monitored using live-cell imaging. After 14 h, the cell culture 
medium was replaced with fresh medium containing vehicle (DMSO) or Nutlin-3a (5 or 
10 μM), and the monitoring of cell proliferation continued. In EV-expressing cells, the 
inhibitory effect of Nutlin-3a on cell proliferation was substantial (Figure 3-6a). In cells 
overexpressing NR4A2, Nutlin-3a–induced inhibition of cell proliferation was attenuated 
at both concentrations of Nutlin-3a tested (Figure 3-6b). At the end of the real-time 
monitoring period (108 h), the cells were collected and their gene expression was 
examined to confirm that NR4A2 expression was increased in cells transduced with 
NR4A2-expressing lentivirus (Figure 3-6c). These data indicate that overexpression of 
NR4A2 attenuates the inhibitory effect of Nutlin-3a on cell proliferation. Together, our 
data are consistent with the known oncogenic role of NR4A2 and, for the first time, 
identify miR-34 as a negative regulator of NR4A2 and reveal a novel functional network 
linking p53, miR-34, and p53. 
 
 
Discussion 
 
 Over the past decade, it has become increasingly evident that miRNA 
dysregulation plays an important role in human disease, including the development, 
progression, and therapeutic resistance of cancer. This process can be quite complex, as 
overlapping miRNA-mRNA networks can be formed, with a single miRNA having 
multiple targets or a single mRNA being a target for multiple miRNAs [250]. Research 
on miRNA regulation and the validation of biological targets has continued to increase in 
an effort to understand the multiple cellular pathways that are affected by specific 
miRNAs, and this area remains of particular interest as additional miRNA-based 
therapies are investigated and placed into clinical trials [251, 252]. 
 
 The NR4A family of orphan nuclear receptors has been studied extensively in 
various cancer models, and its regulation and function have been connected to multiple 
oncogenic and tumor suppressive pathways [45]. However, the contribution of miRNAs 
to the expression of the NR4A family is unclear. In this report, we have presented a novel 
p53–miR-34 regulatory mechanism of the orphan nuclear receptor NR4A2, in which 
miR-34 directly and negatively regulates NR4A2, which is itself able to repress p53-
induced gene expression to rescue the inhibition of cell proliferation (Figure 3-7). This is 
the first miRNA to be characterized as targeting a member of the human NR4A family 
[239, 240]. 
 
 Based on the known roles of NR4A2 in oncogenic processes within cancer, we 
posited that a likely candidate miRNA would be one that harbored tumor-suppressive 
functions and was downregulated in cancer, consequently leading to upregulation of 
NR4A2. As presented here, we identified and described the direct regulation of NR4A2 
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Figure 3-6. Overexpression of NR4A2 attenuates Nutlin-3a sensitivity.  
HCT116 cells were transduced for 16 h overnight with lentivirus expressing empty vector 
(EV) or 3xFlag-NR4A2 (NR4A2). The cell medium was then changed, and the cells 
remained in culture for a total of 48 h. The cells were then reseeded into plates and the 
cell confluence was monitored using an IncuCyte ZOOM imaging system. After 14 h, the 
cell medium was replaced by medium containing vehicle (DMSO) or Nutlin-3a (5 or 10 
μM) (indicated by Tx and arrow). The cell confluence for EV-expressing (a) or NR4A2-
expressing (b) cells was monitored for a total of 108 h. (c) The cells were then collected 
and expression of NR4A2 was determined using TaqMan qPCR probes (normalized to 
ACTB). The value for DMSO-treated EV was set as 1. 
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Figure 3-7. Graphical summary.  
Here, we describe a novel miR-34 regulatory mechanism of NR4A2 that can act 
downstream of p53 activation. Additionally, our studies extend the finding that NR4A2 
can suppress p53 expression and transcriptional targets, including Nutlin-3a–induced 
activation of mir-34a. The p53–miR-34 regulation of NR4A2 may serve as a protective 
mechanism to prevent p53 suppression by NR4A2, in addition to suppressing other 
tumorigenic properties of NR4A2. The long arrow indicates activation; the blunt arrows 
indicate inhibition; the blunt arrow with the dotted line highlights the inhibition of 
NR4A2 by miR-34 that indirectly activates p53. As tumors lose expression of mir-34, the 
expression and function of NR4A2 may become enhanced, shifting the balance from 
tumor suppression to tumor progression. 
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by miR-34, a well-described tumor suppressor–like miRNA that targets genes involved in 
cancer progression and is increasingly being exploited for its therapeutic advantage [233]. 
Whereas other putative miRNAs were identified as targeting NR4A2, we focused on the 
miR-34 family because of the known role of NR4A members in inhibiting p53 [95, 150] 
and the positive regulation of miR-34 by p53 [70], thereby framing our discovery of the 
regulation of NR4A2 by miR-34 as a possible feedback mechanism. The miR-34 
isoforms, predominantly mir-34a, have tumor suppressor functions in multiple cancer 
types, which is sometimes attributed to their p53 status [253, 254], though the 
mechanisms of chromosomal deletion or epigenetic silencing are also major contributors 
[73, 74, 237, 238], and miR-34 expression is prognostic for patient outcome or relapse 
[254-257]. Likewise, several studies have demonstrated the ability of miR-34a restoration 
to sensitize cells to chemotherapeutic agents, including erlotinib [258], 
Adriamycin/doxorubicin [259], and 5-FU [260]. By using a colorectal cancer cell line 
pair that was sensitive or resistant to 5-FU, Akao et al. demonstrated that miR-34a was 
significantly downregulated in the resistant cells, and this was accompanied by increased 
expression of SIRT1, a target of miR-34. The expression of endogenous miR-34a 
remained low in 5-FU–resistant cells treated with 5-FU, and the restoration of miR-34a or 
knockdown of SIRT1 in the resistant cells overcame their resistant phenotype. In light of 
this observation, it would be interesting to study the relationship of miR-34 and NR4A2 
with respect to chemoresistance, as increased NR4A2 expression is correlated with worse 
patient outcomes with regard to 5-FU therapy [93, 94, 230, 231]. 
 
 By using an in vitro luminescence reporter-based screening assay and three 
computer-based prediction algorithms [242-245], we identified miR-34c as a putative 
regulator of NR4A2 via its 3′ UTR region (Figure 3-1 and Table 3-1). This regulatory 
effect was confirmed by using mutagenesis of the predicted miRNA recognition element 
that is complementary to the miR-34 seed region. Other miRNAs from this screen have 
been evaluated using computer-based and mutagenesis approaches (Table 3-1), and the 
functional significance of these miRNA regulators of NR4A2 remains to be elucidated in 
future studies. Using publically available data, we found a weak negative (inverse) 
correlation of miR-34a with NR4A2 (Figures A-1 and A-2), which was similar to the 
correlations of miR-34a with other known miR-34 target genes, such as AXL [246] and 
SIRT1 [235], although NOTCH1 [259] did not show a negative correlation as expected. 
Interestingly, the patient sample data demonstrated two populations of TP53-expressing 
cells, and when we considered only those patient tumor samples with normal levels of 
TP53, the correlation became stronger. As we would hypothesize, there was a positive 
correlation of NR4A2 with AXL and SIRT1 since these genes share a common miRNA 
regulator, miR-34. Consistent with our data in Figures 3-4d and 3-5e, the level of NR4A2 
was negatively correlated to that of TP53 (Figure A-2). 
 
 The next objective was to determine whether miR-34 could regulate endogenous 
NR4A2, at both mRNA and protein levels. Indeed, overexpression of mature miR-34 
isoforms reduced the endogenous levels of NR4A2 mRNA and protein in both wild-type 
and p53-deficient cells (Figures 3-2 and A-4). This would be expected, as forced 
expression of exogenous miR-34 bypasses the requirement for p53. Additionally, miR-34 
overexpression enhanced the p53 activity in wild-type cells, probably because of the 
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known regulatory effect of miR-34 on negative regulators of p53 (Figures 3-2 and A-3). 
This effect is largely the result of increased p53 protein levels rather than substantial 
changes in TP53 transcript levels (Figure A-3). The effect of miR-34 on NR4A2 was not 
as dramatic in the HCT116 p53 wild-type cells, especially at a later time point (24 h) 
(Figure 3-2c), possibly because the lower levels of NR4A2 in these cells no longer 
respond to exogenous miR-34 expression after the initial transfection, although reduced 
protein expression was observed at 48 h post-transfection (Figure 3-2e). This effect 
could also result from the delicate balance of NR4A2 expression being regulated directly 
by miR-34 or indirectly through cellular stress. Correspondingly, RKO p53 wild-type 
cells had higher levels of endogenous NR4A2 and responded better to miR-34 mimics 
than their p53-deficient counterpart (Figure A-4), further supporting the notion that 
endogenous levels of NR4A2 affect its response to exogenous miR-34. 
 
 To further understand the importance of miR-34 regulation of NR4A2 in the 
cellular context, we examined the relationship between endogenous miR-34 and 
endogenous NR4A2 by using our isogenic cell line pairs that possess wild-type or deleted 
TP53. One interesting observation was that treating HCT116 cells with Nutlin-3a at an 
early time point (24 h) led to increased NR4A2 expression, but the opposite effect was 
observed at a later time point (48 h) (Figure 3-3d). Consistent with this result, the 
NR4A2 protein expression was also reduced after 48 h of Nutlin-3a treatment in WT cells 
(Figure 3e). The NR4A family are immediate-early genes that are inducible by many 
stimuli, including cell stress and cytotoxic agents [78], whereas Nutlin-3a has a p53-
independent role and can induce a DNA damage response leading to cell cycle arrest 
[261]. One of these properties might account for the earlier induction of NR4A2 by 
Nutlin-3a, as the NR4A family mediates DNA double-strand break repair [201]. This 
hypothesis could be further tested by using MDM2-deficient cells to determine if these 
effects are independent of the primary role of Nutlin-3a in Mdm2 inhibition. 
 
 Finally, we investigated the previously reported inhibitory effect of NR4A2 on 
p53 activation [95] to determine if this regulation had an effect in the cellular context. We 
confirmed that overexpression of exogenous NR4A2 can inhibit p53 induction of target 
genes in response to Nutlin-3a treatment (Figure 3-4) and that the opposite effect is seen 
when NR4A2 expression is reduced by using siRNA (Figure 3-5). Our data indicate that 
this effect might be achieved at least partially through NR4A2 suppression of TP53/p53 
gene expression. Further investigation is warranted to determine if this suppression 
results from direct or indirect repression of the TP53 promoter. The suppressive effect of 
NR4A2 on the expression of p53 and its transcriptional targets was not reflected in 
changes in the binding of p53 to its target gene promoters. However, this finding may 
reflect the sensitivity of the assay, as even in the presence of NR4A2, enough p53 may be 
present to saturate the promoter response elements during Nutlin-3a treatment. It is also 
possible that NR4A2 is not inhibitory to p53 binding but is repressive of p53 
transactivation at its target gene promoters. 
 
 NR4A2 inhibition of the p53 response has previously been investigated only with 
respect to the genotoxic agent doxorubicin; here, we have demonstrated a similar effect 
using a more targeted p53 activator. When cells overexpressing NR4A2 were subjected to 
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prolonged treatment with Nutlin-3a, we observed a substantial rescue of cells from 
Nutlin-3a–induced inhibition of proliferation (Figure 3-6), suggesting that the inhibitory 
effect of NR4A2 on p53 activation is responsible for phenotypic observations that are 
indicative of p53-induced tumor suppression. Interestingly, in cells overexpressing 
NR4A2, NR4A2 expression was increased in Nutlin-3a–treated cells after prolonged 
treatment (Figure 3-6c). This effect may be attributable to the ability of NR4A2 to repress 
the inhibition of cell proliferation, and as the selective pressure of Nutlin-3a is applied to 
all the cells, those cells expressing the highest levels of NR4A2 persist in culture. 
 
 In summary, our study identified and confirmed a novel regulation of NR4A2 by 
miR-34. This regulatory effect is observed in the context of p53 activation, and NR4A2 
itself is able to repress the p53 response. These events can be regarded as a positive 
feedback loop for p53 (Figure 3-7), much like other miR-34 targets that also suppress 
p53 [235, 236]. In tumors expressing wild-type p53, this can serve as a means by which 
p53 can release itself from repression by NR4A2, further enhancing the p53 response. 
Alternatively, cells that contain p53 mutations or that overexpress NR4A2 through other 
means may lack the p53-mediated suppression of NR4A2, allowing NR4A2 to perform 
other oncogenic activities through its role as a transcription factor. As tumors lose 
expression of mir-34, through promoter methylation or the loss of p53, the expression 
and function of NR4A2 may become enhanced, shifting the balance from tumor 
suppression to tumor progression (Figure 3-7), though this may not be directly traceable 
because of the complexity of miRNA-mRNA regulatory networks. 
 
 
Materials and Methods 
 
 
Cell culture 
 
 All cell lines were grown in culture at 37ºC in 5% CO2. Human embryonic kidney 
293T cells (ATCC, Manassas, VA) were grown according to the manufacturer’s protocol. 
Human colorectal carcinoma HCT116 wild-type and TP53−/− isogenic cell lines, which 
were derived from an adult male harboring a mutation in codon 13 of the ras proto-
oncogene, were obtained from the Genetic Resources Core Facility at Johns Hopkins 
University School of Medicine (Baltimore, MD) and grown in McCoy’s 5A medium 
(ATCC) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific Inc., 
Rockford, IL) and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA). RKO 
human colon carcinoma (derived from a female harboring mutations in BRAF, NF1 and 
PIK3CA) and SW48 human colorectal adenocarcinoma (derived from a female harboring 
mutations in CTNNB1, FBXW7 and EGFR) (wild-type and TP53−/−) and HCT116 
(CDKN1A−/− and BBC3−/−) isogenic cell line pairs [262-264] were obtained from 
Horizon Discovery (Cambridge, UK) and grown according to the manufacturer’s 
protocol. Cells collected for RNA and protein extraction were detached with 0.05% 
trypsin-EDTA (Life Technologies). For all luminescence-based assays, the cells were 
plated using phenol-red–free DMEM or RPMI-1640 medium (Life Technologies). 
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3ʹ UTR reporter plasmid and microRNA screen 
 
 The NR4A2 3′ UTR was cloned by GeneCopoeia, Inc. (Rockville, MD), directly 
downstream from a firefly luciferase (Fluc) gene under the control of an SV40 promoter 
in the pEZX-MT01 vector, which also contains a Renilla luciferase (Rluc) gene under the 
control of a CMV promoter (as a transfection control). This reporter construct (WT 
3UTR) was used to identify miRNAs that regulate Fluc activity through binding to the 
NR4A2 3′ UTR and degradation or translational inhibition of fused Fluc mRNA. The 
Rluc activity was used to normalize the Fluc. The 293T cells were cotransfected for 48 h 
with the 3′ UTR reporter plasmid and 75 cancer-related miRNAs selected from a 
previously described library [241] (Table A-1) by using Lipofectamine 2000 (Life 
Technologies) according to the manufacturer’s protocol. Fugene 6 (Promega, Madison, 
WI) was used for transient cotransfection of reporter gene plasmids and miRNAs into 
HCT116 cells according to the manufacturer’s instructions. Dual-Glo luciferase assays 
(Promega, Madison, WI) were performed to measure and calculate the ratios of firefly 
and Renilla luciferase activity. Luciferase activity was measured with an EnVision 2102 
Multilabel Plate Reader (Perkin Elmer Inc., Waltham, MA). 
 
 
miRNA target prediction and mutagenesis 
 
 Three miRNA target-prediction algorithms were used to identify putative miRNA 
regulators of NR4A2: TargetScanHuman, http://www.targetscan.org [242]; miRanda, 
http://www.microrna.org [243]; and PicTar, http://pictar.mdc-berlin.de/ [244]. By using 
these algorithms, a putative seed region was determined and mutated using site-directed 
mutagenesis (Mutagenex, Inc., Piscataway, NJ). Reporter constructs containing either the 
wild-type (WT 3UTR) or mutated (34mut) 3′ UTR were used to demonstrate miR-34 
specificity in the NR4A2 3′ UTR. 
 
 
Molecular cloning 
 
 NR4A2 cDNA was cloned into the pEXM12-3xFLAG (N-terminal) vector 
(GeneCopoeia, Inc.). We used the primers listed in Table A-2 to amplify 3xFLAG-
NR4A2 cDNA from pEX-3xFLAG-NR4A2 by PCR then subcloned it into a pSin-EF2-
IRES-Blast lentiviral expression vector (kindly provided by Dr. Mark E. Hatley). All 
DNA constructs were confirmed by Sanger sequencing. Lentiviral expression plasmids 
were packaged into viral particles using the psPAX2 packaging (Addgene plasmid # 
12260) and pMD2.G envelope (Addgene plasmid # 12259) vectors. 
 
 
miRNA mimics, RNAi, and chemical treatments 
 
 Exogenous expression of mature miRNAs was performed with mirVana mimics 
transfected using Lipofectamine RNAiMAX reagent (Life Technologies). All chemical 
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treatments were performed in full growth medium containing 0.1% dimethyl sulfoxide 
(DMSO; as a negative control) (Thermo Fisher Scientific) or Nutlin-3a (Sigma Aldrich) 
as specified by the experimental design. Small interfering RNA (siRNA) was obtained 
from Dharmacon (Lafayette, CO) and transfected at a concentration of 20 nM using 
Lipofectamine RNAiMAX reagent. 
 
 
RNA extraction and quantitative real-time PCR 
 
 RNA was extracted using Maxwell simplyRNA kits and a Maxwell 16 Instrument 
(Promega). For the experiments that used miRNA mimics, the total RNA (including 
small RNAs) was extracted from the collected cells using miRNeasy Mini kits (Qiagen) 
in accordance with the manufacturer’s instructions. RNA concentrations were measured 
using a NanoDrop 8000 UV-Vis Spectrophotometer (Thermo Fisher Scientific). All 
cDNA used in mRNA and miRNA quantitative real-time PCR (qPCR) analyses was 
synthesized from extracted RNA by using the SuperScript VILO cDNA synthesis kit 
(Life Technologies) according to the manufacturer’s protocol. The mRNA and miRNA 
expression data were generated using Applied Biosystems TaqMan assays (20×) and Fast 
Advanced Master Mix (Life Technologies). Thermal cycling for qPCR was performed 
with an Applied Biosystems 7900HT Fast Real-Time PCR system (Life Technologies) in 
accordance with the TaqMan Fast protocol. 
 
 
Protein extraction and Western blot analysis 
 
 Protein was isolated by incubating cells in Pierce RIPA lysis buffer with added 
Halt Protease Inhibitor cocktail (Thermo Fisher Scientific) for 30 min on ice then 
sonicating the lysate for 10 s at 50% amplitude to shear the DNA. The protein 
concentration was measured using the Pierce BCA Protein Assay (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. 
 
 Protein lysates were resolved on NuPAGE 4–12% SDS-PAGE gradient gels (Life 
Technologies). After electrophoresis was completed, the proteins were transferred from 
the gels to nitrocellulose membranes with an iBlot dry transfer system (Life 
Technologies). Protein gels used for detection of NR4A2 protein were transferred to 
polyvinylidene fluoride (PVDF) membranes using wet transfer for 1 h at 100V constant 
voltage. The specific antibodies used were rabbit anti-NR4A2 (Santa Cruz 
Biotechnology, sc-5568; M-196) (Figure A-8), mouse anti-p53 (Santa Cruz 
Biotechnology, sc-65334; B-P3), rabbit anti-Sirt1 (Santa Cruz Biotechnology, sc-15404; 
H-300), goat anti-PUMAα (Santa Cruz Biotechnology, sc-19187; N-19); rabbit 
anti?acetyl-p53 (Lys382) (Cell Signaling, Danvers, MA, #2525); mouse anti-Gapdh 
(Ambion, Life Technologies); mouse anti-p21 (Oncogene Research Products, Boston, 
MA, OP64); mouse anti–β-actin (Sigma Aldrich, A5441; clone AC-15); and mouse anti-
FLAG (Sigma Aldrich, F1804; clone M2). All antibodies were diluted in Odyssey 
Blocking Buffer (LI-COR Biotechnology, Lincoln, NE). The secondary antibodies were 
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goat anti-rabbit and goat anti-mouse IRDye 800WC or IRDye 680LT (LI-COR). All 
Western blot imaging was conducted using a LI-COR Odyssey Infrared Imaging System. 
 
 
Chromatin immunoprecipitation (ChIP) 
 
 HCT116 cells transduced with pSin-EF2-IRES-Blast empty vector (EV) or 
3xFlag-NR4A2 lentivirus were grown in flasks and treated with vehicle (DMSO, 0.1%) 
or Nutlin-3a (10 μM) for 6 h. The chromatin was then crosslinked with 1% formaldehyde 
for 10 min. Cell extracts were digested for 10 min with 50 units of micrococcal nuclease 
(New England Biolabs, Ipswich, MA) at 37ºC and further sonicated to yield sheared 
DNA fragments with an average length of 200 to 1000 base pairs. The sonicated samples 
were centrifuged to pellet the cell debris, and the supernatant was diluted 7-fold with 
ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-
HCl, pH 8.1, 167 mM NaCl, and protease inhibitor cocktail). The samples were 
precleared with ChIP-grade Protein G agarose beads (Cell Signaling, #9007) in ChIP 
dilution buffer (1:1 ratio). Diluted supernatant (100 μL) was reserved as input (10%) for 
each treatment. Chromatin (1 mL) was used for each immunoprecipitation and was 
incubated overnight at 4ºC with mouse anti-p53 (Santa Cruz Biotechnology, sc-126; DO-
1) or control mouse IgG. The antibody-protein-DNA complexes were precipitated by 
incubation with Protein G–agarose beads for 2 h at 4ºC. The protein-DNA complexes 
were eluted from the beads with elution buffer (1% SDS, 0.1 M NaHCO3). The crosslinks 
were reversed, and DNA was eluted from the protein-DNA complexes by adding 200 
mM NaCl and incubating at least overnight at 65ºC. DNA was recovered and purified 
after protein digestion with Proteinase K at 45ºC for 2 h using the Qiagen DNeasy Blood 
& Tissue Kit (Qiagen Cat. No: 69506). Quantitative real-time PCR was performed to 
determine the changes in p53 occupancy at various known sites of p53 binding. The 
double-negative controls were nonspecific antibody (normal mouse IgG) and primers 
coding for regions that do not interact with p53. The thermal cycling conditions were 
95ºC for 10 min followed by 45 cycles of 25 s at 95ºC, 30 s at 60ºC, and 30 s at 72ºC. 
The primers used are listed in Table A-2. 
 
 
Cell viability assays 
 
 Real-time cell growth in response to the various treatments was measured as the 
degree of cell confluence in culture plates and was determined using an IncuCyte ZOOM 
live-cell imaging system (Essen BioScience, Ann Arbor, MI). Cell proliferation curves 
were plotted using confluence values at specified time points for each treatment. 
 
 
Analyses of expression data from online databases 
 
 The RNASeq and miRNASeq dataset of 164 patients with rectum 
adenocarcinoma was acquired from the TGCA Research Network: 
http://cancergenome.nih.gov/. After log2 transformation of reported normalized_count 
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for mRNA expression and read_per_million_miRNA_mapped for mature miRNA 
expression, a subset of 97 samples with data generated from the HiSeq platform (for a 
consistent and reliable comparison) was investigated. The correlations between the 
expression of miR-34a and NR4A2, as well as other published miR-34 targets—AXL 
[246], NOTCH1 [259], and SIRT1 [235]—and TP53 were determined by the regression 
analysis using Stata software (College Station, TX). 
 
 
Statistical analyses 
 
 All experiments were performed at least three times, and the independent 
replicates are represented as mean ± standard deviation. Data normalization, statistical 
tests used, and representations of P-value are indicated for each figure in the 
corresponding legend. 
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CHAPTER 4.    INVESTIGATING THE EXPRESSION AND FUNCTION OF 
NR4A NUCLEAR RECEPTORS IN RHABDOMYOSARCOMA 
 
 
Introduction 
 
 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, 
affecting 350 children and adolescents per year in the United States [265]. RMS is 
thought to be derived from the skeletal muscle lineage and of the four subtypes 
characterized, two primarily affect children and adolescents—embryonal RMS (ERMS) 
and alveolar RMS (ARMS). ERMS is more common and is less aggressive, with these 
patients usually being younger and having a much better prognosis [266]. Highly 
aggressive ARMS is typically characterized by a fusion gene of PAX3/7-FOXO1 in 80% 
of cases [267], forming a transcription factor capable of driving oncogenic behavior in 
ARMS [268]. Additionally, other molecular signaling defects have been attributed to 
RMS pathogenesis, including Ras, p53, and Sonic hedgehog (Shh) pathways [269]. 
 
 The NR4A orphan nuclear receptor (NR) family, particularly NR4A1 (Nur77) and 
NR4A2 (Nurr1), has been predominantly studied in adult cancers where higher 
expression of both have been observed [86, 270]. Gene knockdown of NR4A1 generally 
inhibits cell growth and increases apoptosis [86], explaining its importance in cell 
proliferation and survival. NR4A1 expression promotes proliferation in a DNA-binding 
and transactivation-dependent manner [271]. Conversely, in hematological malignancies, 
NR4A1, along with NR4A3 (Nor-1), is found to be downregulated or silenced in mouse 
and clinical samples [46]. In agreement with this, NR4A1 and NR4A3 were found to 
regulate the expression of many of the same genes [98], indicating their functional 
redundancy. 
 
 Less is known about how NR4A2 mediates cancer hallmarks. NR4A2 has been 
shown to play a role in anchorage-independent cell growth [88, 89]. Also, there is 
evidence that NR4A2 can mediate cell migration [90], and others show that NR4A2 can 
mediate cell proliferation and xenograft tumor growth [91, 92]. High expression of 
NR4A2 is found in squamous cell carcinoma (SCC) compared to normal tissues from 
patients, leading to increased resistance to 5-fluorouracil [93]. This suggests that NR4A2 
has pro-survival roles or effects on drug resistance [93, 94]. This could be explained 
partly by an interaction with p53, in which NR4A2 inhibits p53 oligomerization to 
suppress its transactivation of target gene BAX, thus protecting cells from doxorubicin-
induced apoptosis [95]. 
 
 Much of these effects are attributable to the interaction of NR4As with various 
oncogene and tumor suppressor pathways, as well as downstream regulation of NR4A 
target genes [45]. The implications of NR4A expression and function in pediatric cancers 
are not known, although we hypothesize that the NR4A receptors will have similar 
functions in rhabdomyosarcoma. In this study, we assessed the expression of NR4A NRs 
in normal muscle and rhabdomyosarcoma cell lines. We found that, compared to normal 
muscle cells, the NR4A NRs are overexpressed in cell lines of RMS origin. When using 
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siRNA to knockdown the expression of the NR4A members, we found that NR4A1 and 
NR4A2 were able to affect cancer-like properties. Both NR4A1 and NR4A2 knockdown 
caused a decrease in cell proliferation, with NR4A2 having a greater effect. This 
observation was also supported by an increase in the percentage of cells in the G1 phase 
of the cell cycle. Only NR4A2 had an effect on cell migration, while both NR4A1 and 
NR4A2 knockdown decreased colony formation. Lastly, we performed a DNA microarray 
to assess the overlapping gene expression profiles among the three NR4A receptors in 
RMS. We found that knockdown of NR4A1 and NR4A3 had similar transcriptome 
profiles, while NR4A2 knockdown had a unique expression signature. Using this 
transcriptome data to further understand the unique and shared target genes of the NR4A 
receptors, particularly those regulated by NR4A2 to affect cell migration, will offer new 
insights into their roles in cancer and metastasis and the potential for therapeutic 
manipulation by small molecules or miRNAs. 
 
 
Results and Discussion 
 
 
NR4A nuclear receptors are overexpressed in RMS 
 
 As summarized by Mohan et al. [270], the NR4A receptors have been shown to 
be highly expressed in many tumor types, mostly those of adult origin, including bladder, 
breast, colon, liver, and lung cancers. We first sought to determine the expression of the 
NR4A subfamily members in RMS cell lines. When comparing the levels of mRNA 
expression, we found that all three NR4As had higher expression in the RMS cell lines 
(RD, Rh41, and Rh30) in comparison to normal skeletal muscle cells (Figure 4-1). The 
expression of both NR4A1 and NR4A2 are higher in the cell models representative of 
ARMS, while NR4A3 was expressed equally among the three cell lines. Considering the 
known roles of NR4A1 and NR4A2 in promoting cancer phenotypes, such as 
proliferation and migration, it is interesting to note that these two NR4A members were 
higher in cell lines of the more aggressive RMS subtype. With the multiple pathways 
known to regulate NR4A expression, it is possible that increased activity of these 
signaling cascades could be the cause of the NR4A overexpression and this remains to be 
determined. 
 
 
Knockdown of NR4A1 and NR4A2 decreases cell proliferation 
 
 We next sought to determine the roles that the overexpressed NR4A receptors 
have in the RMS cell proliferation. Using Rh30, an RMS cell line of the ARMS subtype 
which had the highest expression of the NR4A receptors, we transfected siRNA to 
knockdown the expression of each NR4A receptor (Figure 4-2a). After 48 h of siRNA-
mediated knockdown, we began monitoring cell proliferation using real-time confluence 
measurement. We found that knockdown of NR4A1 or NR4A2 was able to reduce the cell 
proliferation, with NR4A2 knockdown having a greater effect (Figure 4-2b). This data 
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Figure 4-1. NR4A nuclear receptors are overexpressed in rhabdomyosarcoma cell 
lines.  
The expression of NR4A1, NR4A2, and NR4A3 was determined using Taqman qPCR 
probes. The expression of each gene was normalized to GAPDH as an internal control. 
The data is presented as the fold-change over HSkMC cells (as determined by 2−∆∆Ct). 
The statistical significance of the results was calculated using a two-way ANOVA and 
Dunnett’s test for multiple comparisons. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05. 
 
  
 57 
 
 
Figure 4-2. Knockdown of NR4A1 and NR4A2 decreases cell proliferation.  
Rh30 cells were transfected for 48 h with 50 nM non-targeting (NT) or siRNA against the 
NR4A genes. (a) The knockdown of expression was confirmed using Taqman qPCR 
probes. (b) Cells were then plated for real-time confluence determination using an 
IncuCyte HD imaging system. Rh30 (c) or RD (d) cells were transfected for 48 h with 
NT, siNR4A1, or siNR4A2 (25 nM) and DNA content was determined using propidium 
iodide (PI) staining and flow cytometry analysis. 
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corresponds with the known oncogenic-like effects that NR4A1 and NR4A2 demonstrate 
in adult cancer types [86, 270]. 
 
 Additionally, we determined the cell cycle profile of Rh30 and another RMS cell 
line, RD, following knockdown of NR4A1 or NR4A2. We determined that following 
siRNA transfection, the percentage of cells in the G1 phase of the cell cycle was 
increased with a corresponding decrease in the S-phase cell population (Figure 4-2c, d), 
which is indicative of a decreased proliferative capacity. For the instance of NR4A1, this 
is likely explained by the regulation of target genes such as CCND2 (cyclin D2) [16], 
which plays a critical role in the transition of cells from the G1 to S phase of the cell 
cycle. This is also a possible explanation for NR4A2, as it has been previously suggested 
to regulate CCND1 (cyclin D1)-dependent proliferation of lung cancer cells [91]. 
 
 
Knockdown of NR4A2 decreases cell migration 
 
 Next, we sought to characterize the effects of NR4A knockdown on cell migration 
using several assays. We first used siRNA to knockdown each NR4A member in RD 
cells (Figure 4-3a). Following 48 h of siRNA-mediated knockdown, we plated the cells 
for a wound healing assay. Using real-time imaging, we monitored the wound for 96 h 
total, and found that only knockdown of NR4A2 was able to impair the ability for RD 
cells to efficiently reconstitute the wound (Figure 4-3b, c). Additionally, Rh30 cells were 
transfected with siRNA for 48 h and cell migration was determined using a Boyden 
chamber assay in which we allowed the cells to migrate from a serum-free environment 
towards a 10% serum-containing environment. Following 24 h of migration, we 
determined that siNR4A2 transfection was also able to attenuate the amount of cell 
migration through the membrane, which was quantified using image analysis software 
(Figure 4-3d, e). These two assays indicate that NR4A2 is able to mediate the migratory 
capacity of RMS cells, which is in agreement with previous published data in bladder 
cancer [90]. In terms of cancer progression, this could indicate that NR4A2 is involved in 
tumor metastasis in RMS. In contrast, other reports indicate an opposite and repressive 
role of NR4A2 on migration and invasion of adenocarcinoma cells [272], as well as lower 
expression in breast tissue from patients presenting with lymph node metastases [92]. 
These differences could be because of specific roles that are tissue-dependent, similar of 
that to NR4A1 having opposite roles in solid versus hematologic malignancies. 
 
 
Knockdown of NR4A1 and NR4A2 decreases colony formation 
 
 Using the RD and Rh30 cell lines, we again transfected with siRNA targeting the 
NR4A members. After 48 h, we performed a clonogenic assay by sparsely plating a 
minimal amount of cells and allowing them to form adherent colonies over the course of 
10 days. We found that knockdown of NR4A1 could slightly block the formation of cell 
clones in both cell lines, while knockdown of NR4A2 could lead to a much greater 
attenuation of clonogenicity (Figure 4-4). This data also agrees with Figure 4-2, in that 
NR4A2 knockdown had a greater effect on cell proliferation. This further supports the 
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Figure 4-3. Knockdown of NR4A2 decreases cell migration.  
RD cells were transfected for 48 h with 50 nM non-targeting (NT), siNR4A1, or siNR4A2. 
(a) The knockdown of NR4A expression was confirmed using Taqman qPCR probes. (b) 
RD cells were then plated into 24-well ImageLock plates and allowed to reach 
confluence for 24 h. A scratch-wound was then made uniformly in each well and 
monitored in real-time using an IncuCyte HD imaging system to determine relative 
wound confluence. (c) Representative images from real-time monitoring are shown. (d) 
Rh30 cells were transfected with siRNA and we performed a transwell chamber assay 
followed by crystal violet staining. (e) Migrated cells from 3 fields of each replicate were 
counted using ImageJ software. 
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Figure 4-4. Knockdown of NR4A1 and NR4A2 decreases colony formation.  
RD or Rh30 cells were transfected for 48 h with indicated siRNA (50 nM). Cells (2×103) 
were then plated into 6-well plates in normal growth medium and allowed to grow for a 
period of 10 days, with medium changes every 2 days. Colonies were then fixed with 
methanol and stained with crystal violet to image colony formation. 
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proliferative and pro-survival roles of the NR4A receptors, in particular NR4A2, and also 
is supported by the known roles of NR4A2 in transformation [88, 89]. The ability of 
NR4A2 to affect anchorage-independent colony formation in RMS remains to be 
determined. 
 
 
NR4A2 knockdown leads to an altered transcriptional profile 
 
 It is well described that the pro-oncogenic functions of NR4A1 are carried out 
through its target genes, which include CCND2 [16], E2F1 [85], survivin [47], and 
TXNDC5 [48], but the contributions of NR4A2 to gene expression regulation in cancer 
are not well defined To date, a systematic transcriptome study in cancer has not been 
completed for the NR4A family, which could yield insights into shared and unique target 
genes of the NR4A family. To understand how the NR4A members, particularly NR4A1 
and NR4A2, are affecting the cell proliferation and migration in RMS, we performed a 
microarray study in which we used siRNA to knockdown the expression of each NR4A 
member in either single, double, or triple knockdown combinations. Following 48 h of 
siRNA transfection, we confirmed the specificity and efficiency of the siRNA 
combinations (Figure 4-5a). We next performed a microarray study to determine the 
gene expression changes occurring under each condition. Principal component analysis 
(PCA) of the significantly altered genes indicated that the samples containing knockdown 
of NR4A2 clustered together, indicating their similarity of gene expression, while those 
containing knockdown of NR4A1 or NR4A3 also clustered together (Figure 4-5b). This 
supports the current understanding of the NR4A receptors in that NR4A1 and NR4A3 
were previously shown to have redundant roles and regulate up to 97% of the same gene 
transcripts [98]. This finding is also interesting in that the NR4A2 knockdown causes a 
shift in the gene expression profile of significantly altered genes, some of which may 
explain the unique effect that NR4A2 has on cell migration in this study (Figure 4-3). 
Also, when clustering the samples by significantly upregulated and downregulated genes, 
those samples with NR4A2 knockdown clustered together (Figure 4-5c). Several of the 
genes significantly altered by NR4A2 knockdown were involved in cell cycle and 
motility, and the direct regulation of these genes remains to be determined. Many of the 
genes significantly altered by NR4A2 knockdown were increased in expression, which 
could indicate a mechanism of gene suppression by NR4A2. 
 
 
Conclusions 
 
 In this study, we have further described the pro-oncogenic properties of the NR4A 
family, particularly NR4A1 and NR4A2. This body of data expands the known roles of 
this subfamily of NRs into the field of pediatric oncology, where little is known regarding 
the function of NR4A members. Using multiple phenotypic assays, we identified that 
NR4A1 and NR4A2 can promote cancer cell properties such as proliferation through cell 
cycle regulation, migration, and survival and clonogenecity. Additionally, a systematic 
microarray study to identify NR4A regulated genes indicated that the effect of NR4A2 
depletion has drastic effects on gene expression, which might explain its unique role as a 
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Figure 4-5. Gene expression following NR4A knockdown.  
Rh30 cells were transfected for 48 h with siRNA for each NR4A receptor in single, 
double, or triple combinations (25 nM NR4A-specific siRNA, 75 nM total siRNA per 
sample). (a) Knockdown efficiency and specificity was determined. The expression of 
NR4A1, NR4A2, and NR4A3 was determined using Taqman qPCR probes. The expression 
of each gene was normalized to GAPDH as an internal control. The data is presented as 
the fold-change over non-targeting siRNA (as determined by 2−∆∆Ct). (b) Principal 
component analysis was performed on the genes that were significantly upregulated or 
downregulated in any of the siRNA conditions. (c) Fold-change of significantly altered 
genes over non-targeting is presented as a heatmap (log2 fold change; red = ?2.5, blue = 
?2.5). 
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mediator of cell migration in the RMS cells. It remains to be determined which novel 
genes are critical for the effects observed following NR4A knockdown, and if these 
effects are through direct regulation of novel target genes at promoter binding sites. 
 
 
Materials and Methods 
 
 
Cell culture 
 
 All cell lines were grown in culture at 37ºC in 5% CO2. Rh30 and RD 
rhabdomyosarcoma cell lines (ATCC, Manassas, VA) were grown according to the 
manufacturer’s protocol. Rh41 cells were provided by Dr. Peter Houghton and grown in 
RPMI-1640 medium (Life Technologies, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (Thermo Fisher Scientific, Rockford, IL). Human skeletal muscle cells 
(HSkMC; Cell Applications, Inc., San Diego, CA) were cultured according to 
manufacturer’s guidelines. Trypsin (0.05%)-EDTA (Life Technologies) was used to 
detach cells during passaging and cell collection for RNA and protein extraction. Cells 
were grown in the presence of 1% penicillin-streptomycin (Life Technologies) except 
during siRNA transfections. 
 
 
Transfection of siRNA, RNA extraction, and quantitative real-time PCR 
 
 Small interfering RNA (siRNA) was obtained from Dharmacon (Lafayette, CO) 
and transfected at indicated concentrations using Lipofectamine RNAiMAX reagent (Life 
Technologies). Transfections were performed in the absence of antibiotics, and culture 
medium was changed after 16 hours of incubation with lipid-siRNA complexes. Maxwell 
simplyRNA kits and the Maxwell 16 Instrument (Promega, Madison, WI) were used to 
extract RNA from cell samples. RNA concentration was measured using a NanoDrop 
8000 UV-Vis Spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized 
from 2 μg total RNA using the SuperScript VILO cDNA synthesis kit (Life 
Technologies) according to the manufacturer’s protocol.. The mRNA expression was 
determined using Taqman gene expression assays and Fast Advanced Master Mix (Life 
Technologies). The Applied Biosystems 7900HT Fast Real-Time PCR system (Life 
Technologies) was used for qPCR thermal cycling. 
 
 
Cell proliferation and cell cycle assays 
 
 Rh30 cells were transfected with siRNA (50 nM) for 48 h and plated (1×105) into 
6-well plates to determine real-time cell proliferation in response to NR4A knockdown. 
Cell proliferation was measured as cell confluence in culture plates using an IncuCyte 
HD live-cell imaging system (Essen BioScience, Ann Arbor, MI). Cell proliferation 
curves were plotted using confluence measurements at specified time points for each 
siRNA transfection. Cells transfected with siRNA were also collected after 48 h after 
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transfection and DNA content was assessed using propidium iodide (PI) staining. Briefly, 
1×106 cells were washed with PBS and resuspended in PI solution (0.05 mg/mL PI, 0.1% 
sodium citrate, 0.1% Triton X-100). Samples were then treated with RNAse for 30 min at 
room temperature, filtered through 40 μm mesh, and analyzed by flow cytometry. 
 
 
Cell migration assays 
 
 Wound healing assays were performed by plating cells into 24-well ImageLock 
plates (Essen BioScience) and allowing them to reach full confluence. A scratch-wound 
was made using the Essen BioScience Woundmaker to make a consistent scatch across 
the middle of the imaging field. Plates were then monitored in real-time for indicated 
time points and the ability of cells to migrate towards the center of the wound was 
determined using the Essen Cell Migration software module. Boyden chamber migration 
assays were performed by plating 2×104 cells with serum-free medium into transwell 
chambers with a pore size of 8 μm (BD Biosciences, San Jose, CA). Chambers were 
placed in a 12-well plate with 10% serum-containing medium, and cells were allowed to 
migrate towards the serum-containing medium for 24 h. Transwell chambers were then 
fixed with methanol (Sigma Aldrich) for 10 min and stained with 0.4% crystal violet for 
2 h (Sigma Aldrich) and mounted to a glass slide for light microscopy imaging. Three 
fields for each replicate were counted using ImageJ software. 
 
 
Colony formation assay 
 
 A clonogenic assay was used to measure the ability of single cells to grow into 
cell colonies. After indicated siRNA transfection, 2×103 cells were plated into 6-well 
plates in normal growth medium. Culture medium was replaced every 2 days, and 
colonies were allowed to form for a total of 10 days. Colonies were then fixed with 
methanol for 10 min and stained with 0.05% crystal violet for 2 h and plates were 
scanned. 
 
 
DNA microarray 
 
 Rh30 cells were transfected with 25 nM of NR4A-specific siRNA in single, 
double, or triple combinations (75 nM total siRNA) for 48 h, then collected for RNA 
extraction. Total RNAs were amplified and labeled by using a One-Color Low Input 
Quick Amp Labeling kit (Agilent 5190-2305, Santa Clara, CA), followed by hybridizing 
to the SurePrint G3 Human GE 8×60K microarray (Agilent-028004) that contains 42,545 
unique probes targeting 27,958 Entrez genes. Microarrays were scanned by using an 
Agilent array scanner (G2565CA) at 3 μm resolution. Microarray data were extracted by 
Agilent Feature Extraction software (v10.5.1.1) using GE1_107_Sep09 protocol. The 
quantile normalization on log transformed background-subtracted signal intensity was 
performed among all samples, followed by comparison between sets of replicates from 
different experimental groups. The Student’s t-test was used to determine the statistical 
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significance of the difference between the paired samples from three replicates of each 
experiment. The expression of the gene was considered significantly different if p < 0.05 
and expression change is greater than two folds for at least one of the group comparisons. 
The data process and PCA analysis were performed using Partek software (St. Louis, 
MO). Microarray expression data files were deposited in the Gene Expression Omnibus 
(GEO) as series record GSE68458. 
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CHAPTER 5.    DISCUSSION 
 
 
NR4A Regulation by miRNAs in Cancer 
 
 Many studies have suggested a pro-oncogenic role for the NR4A NRs and, as 
such, high expression of these NRs has been identified in multiple tumor types. The 
NR4A members are early induced genes, with increased expression during situations 
such as mitogenic stimulation, stress, or cell death [78]. Because of this, the cause for the 
overexpression of the NR4A members in cancer has been attributed to oncogenic 
signaling pathways [45], mostly those regulated by growth factors. The NR4A members 
are intertwined with these pathways and frequently can exert effects onto the signaling 
pathways as well, including inhibition of tumor suppressor signaling to further enhance 
cell proliferation and survival. 
 
 One area in which research is lacking for the NR4A receptors is in miRNA 
regulation of these NRs, particularly as it relates to cancer. Our lab recently reported that 
NR4A1 is regulated by miR-124 [273], the first characterized miRNA regulator of 
NR4A1. Upon observation of decreased miR-124 and increased NR4A1 in 
medulloblastoma cells, we found that miR-124 overexpression could regulate NR4A1 
directly through its 3ʹ UTR. This was able to cause a decrease in NR4A1 target genes and 
subsequent reduction in cell proliferation and spheroid growth of medulloblastoma cells. 
miR-124 is also reported to target AR to suppress the proliferation of prostate cancer 
[274], and miR-124 can target other pro-oncogenic genes [275, 276]. Another miRNA, 
miR-132, has been characterized as a regulator of NR4A2 [239], although this 
relationship has not been studied in the context of cancer. 
 
 Due to the lack of understanding regarding miRNA regulation of NR4A receptors, 
we chose to investigate possible mechanisms in which dysregulation of a miRNA might 
lead to upregulation of NR4A2 in cancer. We hypothesized for both NR4A1 and NR4A2, 
that putative miRNA regulators of these genes would be characterized as tumor-
suppressor?like miRNAs. Tumor suppressor?like miRNAs are those that usually target a 
gene that is involved in promoting tumorigenesis, and the loss of this tumor-
suppressor?like miRNA leads to an enhancement of oncogene expression. miR-124 and 
miR-132 have both been reported to contain hypermethylation in their promoters [277, 
278], leading to suppression of these miRNAs in cancer, which could in part explain the 
observed upregulation of NR4A1 and NR4A2 in cancers, respectively. This mechanism of 
miRNA silencing is one common method in which tumors lose their expression of tumor-
suppressor?like miRNAs [72]. 
 
 Using a 3ʹ UTR reporter assay, we screened a set of miRNAs that have been 
reported to be involved in cancer, including both oncomiRs and tumor-suppressor?like 
miRNAs. From this screen, our second ranked miRNA hit was miR-34, which is a well-
described p53-regulated miRNA [70, 71]. Due to its direct transcriptional regulation by 
p53, miR-34 is described as a tumor-suppressor-like miRNA, as it targets many genes 
involved in cell proliferation, migration and metastasis, and suppression of apoptosis 
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[75]. Upon p53 activation, miR-34 expression is increased along with other p53 target 
genes [71]. Due to the known involvement of NR4A2 in regulating p53 activity [95], we 
decided to further investigate the miR-34?NR4A2 relationship to determine if a p53-
miR-34?NR4A2 network existed. 
 
 Mutagenesis studies confirmed that miR-34 did indeed regulate NR4A2 through 
its 3ʹ UTR. Overexpression of exogenous miR-34 was able to decrease NR4A2 at both 
gene and protein levels, confirming the regulation of endogenous NR4A2 expression. 
The effects of miR-34 were also confirmed to increase the p53 activity, as indicated by 
increased levels of acetylated p53 and target gene p21. This was likely through the 
observed downregulation of the deacetylase Sirt1 by miR-34 [235], which is a negative 
regulator of p53 activity. 
 
 To determine if the regulation of NR4A2 by miR-34 had biological relevance, our 
next step was to determine their endogenous relationship. To do so, we used a chemical 
activator of p53, Nutlin-3a [247], to induce the endogenous levels of miR-34. To 
determine the p53-mediated effect, we incorporated isogenic cell line pairs which either 
had wild-type p53 or deletion of p53. Using this method, we found that Nutlin-3a could 
suppress NR4A2 expression at the gene and protein levels in cells with wild-type p53, 
but not in the absence of p53. Future studies will aim to determine if the Nutlin-
3a?induced attenuation of NR4A2 expression is solely due to miR-34 following p53 
activation and not because of other off-target effects. To do this, we will utilize a miR-34 
inhibitor or antagomiR to block the endogenously-induced miR-34 during Nutlin-3a 
treatment. Alternatively, we can utilize genetic knockout models [234] or CRISPR-Cas9 
genome editing to determine the NR4A2 levels in response to p53 activation in the 
absence of miR-34. 
 
 In the context of tumorigenesis, we used publically available data to determine if 
the miR-34?NR4A2 relationship was evident based on expression correlations. While 
one might expect correlations to exist between a miRNA and its target genes, this does 
not always hold true, as the miRNA-mRNA regulatory networks are quite complex [250]. 
Also, in CoMeTa analyses [245], NR4A2 did not score as a top hit for miR-34 targets, so 
we did not expect a robust negative correlation of miR-34 and NR4A2. Using a rectum 
carcinoma data set from The Cancer Genome Atlas (TGCA), we found a weak, inverse 
correlation of miR-34 with NR4A2, and this negative correlation was similar to the 
correlations found between miR-34 and its other published target genes. 
 
 Future studies in the lab will involve investigating other miRNAs of interest from 
our initial 3ʹ UTR reporter screen. One miRNA in particular is miR-214, which was also 
highly ranked in our list of putative miRNAs. miR-214 has been reported to have varying 
roles in cancer depending on tissue type [279]. An area of interest is the regulation of 
miR-214 during myogenic differentiation [280, 281]. The dysregulation of muscle 
differentiation is believed to be a key mechanism of rhabdomyosarcoma tumor 
development and efforts are being put forth to target differentiation as a way to force 
cells into a non-proliferative state [282]. As we have also shown through our knockdown 
studies of NR4A2, there could be importance in studying the relationship of miR-214 and 
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NR4A2 in rhabdomyosarcoma, as miR-214 has been reported to be downregulated in 
rhabdomyosarcoma [283]. NR4A1 is also predicted to be a target of miR-214. miR-206, 
which is a well-described ‘myo-miR’ [284, 285] is also predicted to target several NR4A 
members. Studies are currently underway to understand the implications of the NR4A 
family in muscle differentiation and rhabdomyosarcoma development and progression, 
and to determine if the dynamics of the miR-206/214?NR4A relationships are important 
in these processes. 
 
 
NR4A Function in Cancer 
 
 Knockdown and overexpression studies have demonstrated the importance of 
NR4A1 and NR4A2 in promoting cell proliferation, transformation, migration, and 
survival. This effect has been attributed to NR4A1 regulation of specific target genes [16, 
47, 48, 85], and several groups have aimed at targeting NR4A1 with small molecules [47-
55] to alter the expression of its critical downstream mediators of oncogenesis. The target 
genes of NR4A2 in cancer have not been well characterized, but NR4A2 has been 
associated with chemoresistance [93, 230, 231], possibly through its inhibition of p53 
[95]. 
 
 
NR4A2 and p53 suppression 
 
 Corresponding to the previous identification of NR4A2-mediated suppression of 
p53 activity in response to doxorubicin [95], we found that NR4A2 could also suppress 
Nutlin-3a?induced p53 activity. Overexpression of NR4A2 led to an attenuation of p53 
target gene p21, while knockdown of NR4A2 further enhanced the Nutlin-3a effect, 
suggesting an overall suppressive function of NR4A2. Using chromatin 
immunoprecipitation (ChIP), we were not able to clearly see an effect of p53 recruitment 
to target gene promoters in response to NR4A2 overexpression. Since NR4A2 expression 
is higher in cancer cells, another strategy that we could take is to perform the ChIP during 
knockdown of NR4A2 to determine if this can enhance the p53 association with gene 
promoters, either in the absence or presence of Nutlin-3a treatment. We also observed a 
reduction in both the p53 gene and protein levels in response to NR4A2 overexpression. 
Other mechanistic studies should be performed to clearly determine how NR4A2 is 
mediating its suppressive effect on p53 and its subsequent activation. 
 
 In terms of biological outcome, we found that overexpression of NR4A2 could 
also rescue cells from Nutlin-3a?induced inhibition of cell proliferation. After prolonged 
treatment and observation, we determined that overexpression of NR4A2 could suppress 
the p53 activity as indicated by reduced p21 and miR-34 expression. This model fits with 
the known involvement of NR4A2 with chemoresistance to 5-flurouracil [93, 230, 231], 
and more studies should be completed to determine the relationship of NR4A2 and miR-
34 in cell and mouse models of drug resistance. 
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 These findings hint to a possible feedback loop involving p53, miR-34, and 
NR4A2. Future studies related to this research could be to determine if NR4A2 can 
mediate effects in cancer depending on the p53 status. This would determine to what 
extent the effects of NR4A2 on chemoresistance, proliferation, and migration are 
mediated through p53. Additionally, an examination in patient tumor samples should be 
done to determine the correlation of NR4A2 expression as it relates to the p53 status and 
miR-34 expression. 
 
 
NR4A receptors in rhabdomyosarcoma 
 
 Using cell models of rhabdomyosarcoma (RMS), we sought to understand the 
expression and function of the NR4A receptors. We found that the NR4A receptors 
generally had higher expression in the RMS cell lines when compared to normal muscle 
cells. Knockdown of NR4A1 and NR4A2 was able to reduce cell proliferation and 
clonogenicity of RMS cells, with NR4A2 knockdown having the greater effect. 
Additionally, only NR4A2 was able to affect cell migration, which is supported by a 
previous finding of NR4A2 involvement in migration of bladder cancer cells [90]. 
 
 To begin to understand how the NR4A receptors mediate their pro-oncogenic 
effects in the RMS cells, we performed a microarray study in which we knocked down 
the NR4A receptors in single, double, or triple combinations. Not surprisingly, the cells 
containing NR4A1 and NR4A3 knockdown tended to cluster together, while those with 
NR4A2 had a distinct gene expression profile. Of the significantly altered genes, many of 
those altered by NR4A2 knockdown were increased in expression, suggesting a possible 
role of NR4A2 in gene suppression which is reported for other nuclear receptors. A small 
cluster of genes were identified to be downregulated specifically by NR4A2 knockdown, 
and these genes will be validated for direct promoter regulation by NR4A2 to determine 
if they are true target genes. 
 
 The potential NR4A2-specific target genes from our microarray screen are of 
interest, and determining the importance of these genes as downstream mediators of 
NR4A2 activity could explain the role that NR4A2 has on cell migration in our 
experiments utilizing RMS, as none of the other NR4A members could affect this 
phenotypic response. It will also be critical to determine if NR4A2 can mediate its effects 
on proliferation and migration in a DNA-binding?dependent manner, which will require 
the use of DNA-binding mutants. This is probable due to fact that the RMS cell lines 
used contain mutations of p53 [286], so the effects of NR4A2 in these models is likely 
not due to the p53-NR4A2 relationship we have reported. Additionally, determining if 
upstream regulation of NR4As by miRNAs affects downstream transcriptional targets 
would give insights into coregulated gene expression cascades or networks. 
Understanding the effects of NR4A on these downstream mediators, either through 
miRNA regulation or small molecule inhibitors, can yield valuable information into 
potential uses as biomarkers or new biological targets. 
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Table A-1. List of miRNAs screened. 
 
miRNA ID mirBase v14.0 Accession # Log2 fold change Std. dev. P-value Significance 
hsa-miR-335 MIMAT0000765 −0.475 0.0223 < 0.0001 **** 
hsa-miR-34c MIMAT0000686 −0.475 0.1028 < 0.0001 **** 
hsa-miR-144 MIMAT0000436 −0.444 0.0696 < 0.0001 **** 
hsa-miR-214 MIMAT0000271 −0.379 0.0942 0.0002 *** 
hsa-miR-191 MIMAT0000440 −0.371 0.1471 0.0002 *** 
hsa-miR-15a MIMAT0000068 −0.362 0.0343 0.0004 *** 
hsa-miR-155 MIMAT0000646 −0.361 0.0926 0.0004 *** 
hsa-miR-20a MIMAT0000075 −0.355 0.0296 0.0005 *** 
hsa-miR-25 MIMAT0000081 −0.352 0.128 0.0006 *** 
hsa-miR-122 MIMAT0000421 −0.348 0.0902 0.0007 *** 
hsa-miR-140 MIMAT0000431 −0.333 0.015 0.0016 ** 
hsa-miR-17 MIMAT0000070 −0.325 0.0957 0.0024 ** 
hsa-let-7b MIMAT0000063 −0.314 0.0205 0.0039 ** 
hsa-miR-363 MIMAT0000707 −0.303 0.1958 0.0066 ** 
hsa-miR-218 MIMAT0000275 −0.297 0.0494 0.0085 ** 
hsa-miR-9 MIMAT0000441 −0.297 0.0711 0.0086 ** 
hsa-miR-132 MIMAT0000426 −0.297 0.1684 0.0086 ** 
hsa-miR-21 MIMAT0000076 −0.274 0.0699 0.0224 * 
hsa-miR-184 MIMAT0000454 −0.268 0.0717 0.0289 * 
hsa-miR-32 MIMAT0000090 −0.266 0.0533 0.0317 * 
hsa-miR-148a MIMAT0000243 −0.251 0.1481 0.0553 ns 
hsa-miR-10b MIMAT0000254 −0.237 0.0745 0.0892 ns 
hsa-miR-30c MIMAT0000244 −0.228 0.138 0.1213 ns 
hsa-miR-210 MIMAT0000267 −0.213 0.0814 0.1895 ns 
hsa-miR-128b MIMAT0031095 −0.203 0.0917 0.2513 ns 
hsa-miR-92a MIMAT0000092 −0.199 0.0536 0.2774 ns 
hsa-miR-133b MIMAT0000770 −0.195 0.1246 0.3096 ns 
hsa-miR-143 MIMAT0000435 −0.184 0.1607 0.3967 ns 
hsa-miR-150 MIMAT0000451 −0.173 0.1322 0.5083 ns 
hsa-miR-29a MIMAT0000086 −0.171 0.1333 0.5269 ns 
hsa-miR-222 MIMAT0000279 −0.164 0.0358 0.5981 ns 
hsa-miR-98 MIMAT0000096 −0.161 0.0807 0.6303 ns 
hsa-miR-18a MIMAT0000072 −0.158 0.046 0.6677 ns 
hsa-miR-181b MIMAT0000257 −0.143 0.1663 0.8227 ns 
hsa-miR-27a MIMAT0000084 −0.139 0.1611 0.8586 ns 
hsa-miR-301a MIMAT0000688 −0.132 0.1036 0.9086 ns 
hsa-miR-130a MIMAT0000425 −0.127 0.0528 0.9394 ns 
hsa-miR-206 MIMAT0000462 −0.126 0.1139 0.9474 ns 
hsa-let-7e MIMAT0000066 −0.119 0.1312 0.9705 ns 
hsa-miR-127 MIMAT0004604 −0.117 0.2329 0.9794 ns 
hsa-miR-205 MIMAT0000266 −0.114 0.113 0.9807 ns 
hsa-miR-23b MIMAT0000418 −0.113 0.0235 0.9812 ns 
hsa-miR-19a MIMAT0000073 −0.112 0.1182 0.982 ns 
hsa-miR-212 MIMAT0000269 −0.106 0.1397 0.9843 ns 
hsa-miR-34a MIMAT0000255 −0.089 0.2004 0.9983 ns 
hsa-miR-126 MIMAT0000445 −0.078 0.1309 0.9986 ns 
hsa-miR-193b MIMAT0002819 −0.072 0.1828 0.9988 ns 
hsa-miR-16 MIMAT0000069 −0.067 0.0803 0.9989 ns 
hsa-miR-100 MIMAT0000098 −0.059 0.0657 0.999 ns 
hsa-miR-135b MIMAT0000758 −0.059 0.0515 0.999 ns 
hsa-miR-193a MIMAT0004614 −0.057 0.0549 0.9991 ns 
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Table A-1. (Continued). 
 
miRNA ID mirBase v14.0 Accession # Log2 fold change Std. dev. P-value Significance 
hsa-miR-146b MIMAT0002809 −0.051 0.1313 0.9992 ns 
hsa-miR-125a MIMAT0000443 −0.042 0.088 0.9994 ns 
hsa-miR-181d MIMAT0002821 −0.035 0.1467 0.9995 ns 
hsa-miR-7 MIMAT0000252 −0.031 0.0815 0.9996 ns 
hsa-let-7f MIMAT0000067 −0.029 0.1111 0.9996 ns 
hsa-miR-96 MIMAT0000095 −0.024 0.1182 0.9997 ns 
hsa-let-7d MIMAT0000065 −0.013 0.0577 0.9999 ns 
hsa-miR-373 MIMAT0000726 −0.002 0.0811 > 0.9999 ns 
hsa-miR-183 MIMAT0000261 0.0092 0.1278 0.9998 ns 
hsa-miR-378 MIMAT0000732 0.0094 0.0893 0.9998 ns 
hsa-let-7a MIMAT0000062 0.0112 0.1743 0.9997 ns 
hsa-miR-203 MIMAT0000264 0.0438 0.1135 0.9991 ns 
hsa-let-7c MIMAT0000064 0.0536 0.1421 0.999 ns 
hsa-miR-200c MIMAT0000617 0.0546 0.1715 0.999 ns 
hsa-miR-29b MIMAT0000100 0.0596 0.0889 0.9988 ns 
hsa-miR-10a MIMAT0000253 0.072 0.1945 0.9985 ns 
hsa-miR-146a MIMAT0000449 0.0773 0.1303 0.9983 ns 
hsa-miR-199a MIMAT0000232 0.1012 0.0518 0.9824 ns 
hsa-miR-181c MIMAT0000258 0.167 0.1058 0.4707 ns 
hsa-miR-124 MIMAT0000422 0.2023 0.0932 0.1954 ns 
hsa-miR-20b MIMAT0001413 0.2176 0.0801 0.1232 ns 
hsa-miR-27b MIMAT0000419 0.2827 0.1402 0.0107 * 
hsa-miR-148b MIMAT0000759 0.3025 0.0726 0.0043 ** 
hsa-miR-181a MIMAT0000256 0.3268 0.0741 0.0014 ** 
 
****, P ≤ 0.0001; ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05; ns, P > 0.05 
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Figure A-1. Correlation of miR-34a and NR4A2 expression in rectum 
adenocarcinoma patients.  
(a) Regression analysis was used to determine the correlation between expression of miR-
34a and NR4A2 in a subset of 97 patient samples from the TGCA rectum adenocarcinoma 
dataset. (b) TP53 expression was determined using HiSeq data from the 97 patient 
samples and the distribution of expression is represented. (c) Regression analysis was 
used to determine the correlation between expression of mir-34a and NR4A2 in a smaller 
subset of 74 patient samples with higher TP53 expression. 
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Figure A-2. miR-34a correlation matrix in rectum adenocarcinoma patients.  
(a) Expression correlations between miR-34a and indicated genes were determined using 
regression analysis in a subset of 97 patient samples from the TGCA rectum 
adenocarcinoma dataset. (b) Regression analysis was used to determine the correlation 
between expression of miR-34a and indicated genes in a smaller subset of 74 patient 
samples with higher TP53 expression. 
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Figure A-3. Overexpression of miR-34 increases p53 protein and acetylation 
levels.  
(a) Control (labeled as CmiR) or miR-34a-5p (34a) or miR-34c-5p (34c) mimics (10 nM) 
were transfected into HCT116 isogenic cell lines for 48 h, after which SDS-PAGE gel 
electrophoresis and Western blot analysis of the indicated proteins from whole cell 
lysates (45 μg) was performed. (b) A schematic of the previously described positive-
feedback mechanisms involving p53 and its transcriptionally regulated miRNAs. (c) 
Expression of TP53 was determined using a TaqMan qPCR probe after transfection of 
control (CmiR), miR-34a-5p, or miR-34c-5p mimics (10 nM) into HCT116 wild-type 
(WT) cells for the times indicated. Gene expression was normalized to GAPDH. The 
value for the CmiR-transfected WT cells at each time point was set as 1. The statistical 
significance of the results for miR-34 transfections, compared to those for the control, at 
each time point was calculated using a one-way ANOVA and Dunnett’s test for multiple 
comparisons.**, P ≤ 0.01; *, P ≤ 0.05. (d) Whole-cell lysates (45 μg) from HCT116TP53–/– 
(TP53–/–) and HCT116 wild-type (TP53+/+) cells transfected for 48 h with CmiR, miR-
34a-5p (34a), or miR-34c-5p (34c) mimics were assessed for expression of Sirt1 and β-
actin protein by performing SDS-PAGE gel electrophoresis and Western blot analysis. 
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Figure A-4. Overexpression of miR-34 decreases NR4A2 in RKO colorectal cancer 
cells.  
Mature miR-34a-5p and miR-34c-5p mimics (10 nM) were transfected into RKOTP53–/– 
(KO) or RKO wild-type (WT) cells for 12 or 24 h. Expression of hsa-miR-34a-5p (a), 
hsa-miR-34c-5p (b), CDKN1A (c), and NR4A2 (d) was determined using TaqMan qPCR 
probes. Mature miRNA expression was normalized to RNU48, and CDKN1A and NR4A2 
were normalized to GAPDH. The value for the CmiR-transfected KO cells at each time 
point was set as 1. The statistical significance of the results for miR-34 transfections for 
each cell line, compared to those for the control, at each time point was calculated using a 
two-way ANOVA and Dunnett’s test for multiple comparisons. ****, P ≤ 0.0001; ***, 
P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05. 
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Figure A-5. Nutlin-3a enhances p53 and p21 protein levels in RKO and SW48 
colorectal cancer cell lines. 
RKO (a) and SW48 (b) colorectal cancer cell lines that are isogenic for p53 expression 
(TP53−/−, top; TP53+/+, bottom) were treated for the indicated time periods with vehicle 
(DMSO) (0 μM) or Nutlin-3a (5 or 10 μM). Whole-cell lysates were assessed for 
expression of p53, p21, and Gapdh protein by performing SDS-PAGE gel 
electrophoresis. 
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Figure A-6. p53 activation by Nutlin-3a decreases NR4A2 in RKO and SW48 cell 
lines.  
RKOTP53−/− (KO) and RKO wild-type (WT) (a–c) or SW48TP53−/− (KO) and SW48 wild-
type (WT) cells (d–f) were treated with vehicle control (DMSO) or Nutlin-3a (5 or 10 
μM) for 24 or 48 h. Expression of mir-34a (a, d), CDKN1A (b, e), and NR4A2 (c, f) was 
determined using TaqMan qPCR probes (normalized to GAPDH). The value for the 
DMSO-treated KO cells at each time point was set as 1. The statistical significance of the 
results obtained with Nutlin-3a treatments for each cell line, compared to those obtained 
with DMSO, for each time point was calculated using a two-way ANOVA and Dunnett’s 
test for multiple comparisons. ****, P ≤ 0.0001; ***, P ≤ 0.001; **, P ≤ 0.01. 
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Figure A-7. Overexpression of NR4A2 does not affect binding of p53 to target 
gene promoters.  
HCT116 wild-type cells were transduced with empty vector (EV) or 3xFlag-NR4A2 
(NR4A2) lentivirus. After 16 h, the medium was changed and the cells were grown in 
culture for a total of 48 h. The cells were then reseeded into 150-mm2 flasks and treated 
for 6 h with vehicle (DMSO) or Nutlin-3a (10 μM). The chromatin immunoprecipitation 
protocol was performed and the occupancy of p53 at the p53-free (a), CDKN1A −2242 
(b), CDKN1A −11708 (c), MDM2 (d), and mir-34a (e) promoter regions is shown 
(represented as fold-enrichment over IgG). (f) Nuclear-enriched extracts used as input for 
the ChIP were resolved on a 4–12% SDS-PAGE gradient gel and probed with antibodies 
against Flag (indicating NR4A2), p53, and Gapdh. The statistical significance of the 
results was determined using a two-way ANOVA with Tukey’s multiple comparison test. 
The significance of the differences within each transduction group (****, P ≤ 0.0001; 
***, P ≤ 0.001) and between transduction groups (n.s., P > 0.05) is represented. 
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Table A-2. List of primers used. 
 
Primer name Sequence (5ʹ to 3ʹ) Type Use 
SpeI-3xFlag fwd ATA CTA GTC CAC 
CAT GGA CTA CAA 
AGA CC 
Cloning Subcloned 3xFlag-
NR4A2 into pSIN 
lenti expression 
plasmid 
BamHI-Nurr1 rev ATG GAT CCC TAG 
AAA GGT AAA GTG 
TCC A 
Cloning Subcloned 3xFlag-
NR4A2 into pSIN 
lenti expression 
plasmid 
EF1a fwd seq TCA AGC CTC AGA 
CAG TGG TTC 
Sequencing Confirm cloning of 
3xFlag-NR4A2 into 
pSIN plasmid 
pSIN rev seq CCC TAG ATG CAT 
GCG GAT CCT TCG 
Sequencing Confirm cloning of 
3xFlag-NR4A2 into 
pSIN plasmid 
pEZX-MT01 fwd GAT CCG CGA GAT 
CCT GAT 
Sequencing Confirm seed region 
mutation 
pEZX-MT01 rev TTG GCG TTA CTA 
TGG GAA CAT 
Sequencing Confirm seed region 
mutation 
CDKN1A −3969 bp 
RE fwd (p53-free) 
ACT ATA TGC TCA 
GCC ATT GTG TCT 
GCT 
ChIP 
qPCR 
p53 ChIP of p53-free 
region in CDKN1A 
promoter247 
CDKN1A −3969 bp 
RE rev (p53-free) 
CCC TCA GCA TCA 
GTG TTA CCA ACC 
ChIP 
qPCR 
p53 ChIP of p53-free 
region in CDKN1A 
promoter247 
CDKN1A −2242 bp 
RE fwd 
CTG TGG CTC TGA 
TTG GCT TT 
ChIP 
qPCR 
p53 ChIP of CDKN1A 
promoter247 
CDKN1A −2242 bp 
RE rev 
CCC TTC CTC ACC 
TGA AAA CA 
ChIP 
qPCR 
p53 ChIP of CDKN1A 
promoter247 
CDKN1A −11708 
bp RE fwd 
GAG TGG GTG GCT 
CAC TCT TC 
ChIP 
qPCR 
p53 ChIP of CDKN1A 
promoter247 
CDKN1A −11708 
bp RE rev 
CTC GCA TCA GCA 
ACT CTG G 
ChIP 
qPCR 
p53 ChIP of CDKN1A 
promoter247 
MDM2 p53 RE fwd GAT TGG GCC GGT 
TCA GTG G 
ChIP 
qPCR 
p53 ChIP of MDM2 
promoter248 
MDM2 p53 RE rev CAC AGC TGG GAA 
AAT GCA TGG 
ChIP 
qPCR 
p53 ChIP of MDM2 
promoter248 
mir-34a p53 RE fwd ACG CTT GTG TTT 
CTC AGT CCG 
ChIP 
qPCR 
p53 ChIP of mir-34a 
promoter71 
mir-34a p53 RE rev TGG TCT AGT TCC 
CGC CTC CT 
ChIP 
qPCR 
p53 ChIP of mir-34a 
promoter71 
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Figure A-8. Validation of an anti-NR4A2 antibody.  
HCT116TP53−/− cells were transfected with nontargeting siRNA (Non-Targ.) or siNR4A2 
(20 nM) in 60mm2 dishes. After 24 h of siRNA transfection, 3xFlag-EGFP (Flag-EGFP) 
or 3xFlag-NR4A2 (Flag-NR4A2) were transfected for an additional 48 h. Whole cell 
lysates (45 μg) were resolved on a 4–12% SDS-PAGE gradient gel and transferred to 
PVDF membrane using wet transfer (100V constant for 1 h). Membranes were probed 
with antibodies against Flag (detecting overexpressed NR4A2 or EGFP), NR4A2 
(detecting both endogenous NR4A2 and Flag-NR4A2), and β-actin. The levels of 
endogenous NR4A2 (detected using anti-NR4A2) and Flag-NR4A2 (detected using 
either anti-NR4A2 or anti-Flag) decreased in response to siNR4A2 but not Non-Targ. 
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